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Sebastian Eduardo Carrasco 
ELUCIDATING THE INTERACTION OF BORRELIA BURGDORFERI OSPC WITH 
PHAGOCYTES IN THE ESTABLISHMENT OF LYME BORRELIOSIS 
 
 Lyme disease, the most prevalent vector-borne illness in the United States, is a 
multisystem inflammatory disorder caused by infection with the spirochete Borrelia 
burgdorferi (Bb). This spirochete is maintained in nature through an enzootic cycle 
involving ticks and small mammals. The Bb genome encodes a large number of surface 
lipoproteins, many of which are expressed during mammalian infection. One of these 
lipoproteins is the major outer surface protein C (OspC) whose production is induced 
during transmission as spirochetes transition from ticks to mammals. OspC is required for 
Bb to establish infection in mice and has been proposed to facilitate evasion of innate 
immunity. However, the exact biological function of OspC remains elusive. Our studies 
show the ospC-deficient spirochete could not establish infection in NOD-scid IL2rγnull mice 
that lack B cells, T cells, NK cells, and lytic complement, whereas the wild-type spirochete 
was fully infectious in these mice. The ospC mutant also could not establish infection in 
SCID and C3H mice that were transiently neutropenic during the first 48 h post-challenge. 
However, depletion of F4/80+ phagocytes at the skin-site of inoculation in SCID mice 
allowed the ospC mutant to establish infection in vivo. In phagocyte-depleted SCID mice, 
the ospC mutant was capable to colonize the joints and triggered neutrophilia during 
dissemination in a similar pattern as wild-type bacteria. We then constructed GFP-
expressing Bb strains to evaluate the interaction of the ospC mutant with phagocytes. Using 
 vii 
 
flow cytometry and fluorometric assay for phagocytosis, we found that phagocytosis of 
GFP-expressing ospC mutant spirochetes by murine peritoneal macrophages and human 
THP-1 cells was significantly higher than parental wild-type Bb strains, suggesting that 
OspC has an anti-phagocytic property. This enhancement in phagocytosis was not 
mediated by MARCO and CD36 scavenger receptors and was not associated with 
changes in mRNA levels of TNFα, IL-1β, and IL-10. Phagocytosis assays with HL60 
neutrophil-like cells showed that uptake of Bb strains was independent to OspC. 
Together, our findings reveal that F4/80+ phagocytes are important for clearance of the 
ospC mutant, and suggest that OspC promotes spirochetes’ evasion of macrophages in the 
skin of mice during early Lyme borreliosis.  
 
X. Frank Yang, Ph.D. - Chair 
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CHAPTER I: INTRODUCTION 
Lyme disease 
History and epidemiology of Lyme disease 
 Lyme disease was first reported in the United States in 1975 when Drs. Allen 
Steere and Stephen Malawista described an unusually high incidence of acute arthritis 
among children in Old Lyme, Connecticut (1). A skin rash with an expanding bull’s-eye 
pattern was also reported to precede the onset of arthritic symptoms in 25% of these cases 
(1). Clinical, temporal and spatial findings from this disease outbreak investigation 
allowed Dr. Steere and coworkers to postulate that an infectious agent was responsible 
for this unusually high onset of Lyme arthritis in children. They suspected that this 
infectious agent was transmitted by an unidentified arthropod vector since most cases 
occurred in rural communities near wooded areas with the onset peaking in summer and 
early fall (1). In 1982, Dr. Burgdorfer and colleagues detected and isolated spirochetes 
belonging to the genus Borrelia spp. from the mid-guts of Ixodes ticks (2). This 
spirochetal bacterium was later named Borrelia burgdorferi (3). To date, there are three 
Borrelia species that are known to cause Lyme disease that are transmitted by the hard 
tick Ixodes. B. burgdorferi sensu stricto is the sole agent of Lyme disease in the United 
States while the other two Borrelia species (B. garini and B. afzelii) are found only in 
Europe and parts of Asia (4, 5). 
 Lyme disease became a reportable illness in 1991 and is the most common 
arthropod-borne disease in the United States, with almost 30,000 confirmed cases 
reported each year to the Center for Disease Control and Prevention (CDC) (6). Recently, 
the CDC have estimated that the number of probable infections is around 300,000 
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reported cases annually (7). In terms of its geographic distribution, Lyme disease is 
endemic in the northeastern and northcentral (upper Midwest) region of the United States 
(Figure 1) (6). In 2013, the CDC estimated that 95% of reported and confirmed Lyme 
disease cases were from 14 states, including Connecticut, Maine, Maryland, 
Massachusetts, Minnesota, New Hampshire, New Jersey, New York, Pennsylvania, 
Rhode Island, Vermont, Virginia, and Wisconsin. 
 
Figure 1. Reported Cases of Lyme Disease in the United States, 2013 (CDC Division 
of Vector-borne Infectious Diseases - last accessed February 5, 2015) (8). For each case 
of Lyme disease confirmed by the State Health Departments, one dot is placed randomly 
within the county of the patient’s residence. Cases have been reported in nearly every 
state, but the county of residence is not necessarily the county in which the infection was 
acquired. The greatest number of cases was reported in the northeastern and the upper 
midwestern states. 
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The enzootic life cycle of B. burgdorferi 
 B. burgdorferi circulates in natural enzootic cycles involving Ixodes ticks and a 
wide range of vertebrate hosts. Ixodes scapularis, commonly known as the deer tick or 
Eastern black-legged tick, is the principal arthropod vector responsible for transmitting B. 
burgdorferi to mammals in northeastern and northcentral regions of the United States (3). 
In addition, Ixodes pacificus, the Western black-legged tick, has been reported to 
maintain B. burgdorferi in nature in western areas of United States such as northern 
California, Oregon, and Washington State (9-11). These Ixodes species are considered to 
be three-host ticks since they feed once at each of the three life stages: larvae, nymphs, 
and adults (12). The Ixodes ticks have a 2-year life cycle which begins when adult female 
ticks lay eggs during early spring. After these eggs hatch into larvae during summer, they 
take their first blood meal by feeding on an infectious vertebrate host such as the white-
footed mouse (Peromyscus leucopus), a common natural reservoir for B. burgdorferi in 
the United States (13, 14). After feeding for at least 72 h, engorged larvae drop from the 
host to the ground and become dormant for winter months. In the following late spring or 
early summer, the larvae molt into nymphs, which can then take their second blood meal 
on a competent reservoir host, such as small rodents. After feeding for at least 72 h, 
engorged nymphs detach and drop to the ground and molt into the adult ticks during the 
fall.  At this time, adult ticks feed for the final time on a larger mammal such as a white 
tailed deer (Odocoileus virginianus), which are considered incompetent hosts for B. 
burgdorferi. However, deer play an important role in the maintenance of the tick 
population because adult ticks mate on these animals (15). After mating, the adult female 
ticks fall off the deer and lay eggs prior to dying in the late fall or early spring (13, 16, 
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17). Humans and dogs are considered accidental dead-end hosts within the B. burdorferi 
life cycle and can develop clinical manifestations of disease. Although Ixodes ticks can 
feed on humans in any of the three developmental stages, the nymphal stage is when 
infected ticks are most likely to transmit B. burgdorferi to humans (13, 14).  
Clinical manifestations of Lyme disease 
 The clinical manifestations of Lyme disease in humans are divided in three 
separate stages: early localized infection at the skin (stage 1), disseminated infection 
(stage 2), and late persistent infection (stage 3) (18).  Infection with B. burgdorferi can 
result in dermatologic, musculoskeletal, cardiac, neurologic and/or ocular abnormalities 
(18). Early localized infection develops within the first 30 days after a tick bite and is 
characterized by a cutaneous lesion, called erythema migrans (Figure 2), which is 
reported in 70-80% of infected individuals (19). This cutaneous lesion is accompanied by 
arthralgia, myalgia and/or swollen lymph nodes. Dissemination of spirochetes occurs 
within days to weeks and could be accompanied by different clinical manifestations, 
including secondary annular skin lesions, acute lymphocytic meningitis, cranial 
neuropathy, radiculoneuritis, atrioventricular nodal block, musculoskeletal pain in joint 
and adjacent tissues, and ocular pain and photophobia (18). Chronic or persistent clinical 
manifestations can occur months or years after the infection in untreated individuals or in 
10% of infected individuals that fail to respond to antibiotic therapy. The most common 
manifestation of late infection is monoarticular or oligoarticular arthritis (20).  Other 
reported clinical manifestations of persistent infection are peripheral and central nervous 
system abnormalities (e.g. encephalomyelitis, encephalopathy, and axonal 
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polyneuropathy) and cardiac abnormalities (e.g. atrioventricular blocks and 
myopericarditis) (21, 22). 
 
 
Figure 2.  Macroscopic and microscopic features of erythema migrans of patients 
exposed to or infected with B. burgdorferi. A) Representative example of erythema 
migrans (EM) lesion on patient arm characterized by red “bull’s-eye” macule 
(photograph was reproduced from (23)). B) Biopsy specimen of EM lesion characterized 
by perivascular infiltrates of mononuclear cells (blue color using H&E staining) are 
observed throughout the dermis. C) Immunohischemical staining of skin biopsy 
specimen that shows large numbers of CD68+ macrophages (brown staining) and 
moderate numbers of CD3+ T cells (D, brown staining) in perivascular infiltrate 
(photomicrographs were reproduced from  (24)).   
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Diagnosis of Lyme disease 
 Currently, the CDC recommends that practitioners diagnose Lyme disease based 
on clinical evidence of EM lesion, late clinical manifestations involving the 
musculoskeletal, nervous or cardiovascular system, laboratory evidence of infection, and 
known exposure to potential tick habitats in an endemic Lyme disease region (within 30 
days before onset of EM). Laboratory assays recommended by the CDC that are used to 
define a Lyme disease case include a positive culture for B. burgdorferi or a positive 
serology for evidence of antibodies against this spirochete (25). Although cultivation of 
B. burgdorferi has been reported from various clinical specimens, including skin 
biopsies, blood, plasma, sera, and other fluids (26-29), this method is not sensitive for 
isolation of spirochetes in patients with disseminated and persistent infection due to the 
sparseness of organisms in tissues or technical limitations associated with laboratory 
contamination of patient samples (26, 27). However, culture can be a highly sensitive tool 
for detection of B. burgdorferi from skin biopsies collected from patients with acute EM 
whose diagnosis was based mostly on the clinical recognition of this lesion (26, 30).  
 Detection of antibodies to B. burgdorferi by ELISA and immunoblot are currently 
the only standardized tools for laboratory diagnosis of Lyme disease in humans. The 
CDC recommends a two-step process when testing blood from individual Lyme disease 
patients and conducting epidemiological surveillance of Lyme disease (25). The ELISA 
assays use whole cell lysates or purified recombinant B.burgdorferi antigens as sources 
of substrate for detection of IgM and IgG antibodies individually or in combination (25, 
26). If the result from ELISA is positive or intermediate (weak positive), then 
immunoblotting is used as a confirmatory assay. The second step uses an immunoblot 
 7 
 
assay that allows the assessment of antibodies against specific B. burgdorferi antigens 
(Table 1). This assay has contributed to determining which antigens of B. burgdorferi are 
immunodominant at different stages of infection. For example, OspC is an 
immunodominant antigen that elicits a strong IgM reactivity during early stages of 
infection while most responses to B. burgdorferi immunodominant antigens develop at 
different time points during later stages of disease (26).  Although serology is the method 
of choice for laboratory diagnosis of Lyme disease, other methods such as PCR have 
been developed for detection of B. burgdorferi DNA from samples and are employed in 
research settings and reference laboratories (25).  
Table 1. Borrelia burgdorferi antigens of diagnostic significance 
Antigen Other designation Molecular size 
(kDa) 
Gene location
93 P63/100 93 Chromosome 
66 P66, αIIbβ3 integrin binding protein 66 Chromosome 
58  58 Chromosome 
BBK32 P47, Fibronectin binding protein 47 lp36 
45  45 Chromosome 
VlsE Antigenic variation protein 35-43 lp28-1 
41 FlaB, Flagellin 41 Chromosome 
39 BmpA, Laminin binding protein 39 Chromosome 
34 OspB 34 lp54 
31 OspA 31 lp54 
28 OspD 28 lp38 
23 OspC 21-25 cp26 
DbpA P17, Decoring binding protein A 17-18 lp54 
17 RevA, Fibronectin binding protein 17 cp32 
ErpA OspE related protein 17 cp32 
  
 Although this two-step serology approach is highly sensitive and specific for 
detection of antibodies to B. burgdorferi after the first 3-4 weeks of infection in Lyme disease 
patients, this approach is not sensitive for detection of B. burgdorferi-specific antibodies 
within the first 2-3 weeks after infection in patients with acute EM and/or early neurological 
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manifestations (25, 26). These serological assays are not going to test positive until an 
infected individual has had time to develop antibodies against most B. burgdorferi antigens 
used for the serodiagnosis of Lyme disease (25, 26). In addition, the use of B. burgdorferi 
antigens for the early serodiagnosis of Lyme disease has been a subject of considerable 
debate as some of these antigens are either highly heterogenous among strains such as OspC 
or crossreactive with other bacterial antigens such as flagellar proteins (26). Therefore, 
research efforts have focused on developing serological assays against new recombinant 
antigens and synthetic peptides to improve the detection of B. burgdorferi-specific antibodies 
during early infection (25). Serodiagnosis of early Lyme borreliosis is important in the 
management of disease progression as infected individuals at this disease stage are 
completely cured after antibiotic treatment (18). Our findings in part II of this dissertation 
discuss the potential use of B. burgdorferi EF-Tu as an early serodiagnostic marker of 
Lyme borreliosis.  
The murine model of Lyme disease 
 The use of laboratory inbred mouse strains has been extremely useful for 
understanding many features of the immune response and pathogenesis of human Lyme 
arthritis and carditis (31-33).  This mouse model also recapitulates other clinical 
manifestations of Lyme disease, including vasculitis, myositis, and peripheral neuritis 
(31, 33, 34).  However, mice do not manifest the EM lesion that is observed in most 
infected individuals or develop central nervous system disease and chronic Lyme arthritis 
that may occur in some human patients (34).   
 To establish this mouse model several host and bacterial factors were initially 
tested. Early studies into the host-pathogen interaction of B. burgdorferi showed that 
disease severity in mice is influenced by genotype, immune status, age, B. burgdorferi 
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isolate and passage history, infectious dose and route of inoculation, and site of 
inoculation (35). To date, it is well-accepted that inbred mouse strains are equally 
susceptible to B. burgdorferi infection, but the susceptibility of arthritis and carditis is 
dependent on the mouse genotype (31, 36). The C3H/HeN and C3H/HeJ mice are the 
primary strains to study the pathological changes in the heart and joints since they 
develop severe carditis and arthritis in the tibio-tarsal joints by 2-3 weeks after B. 
burgdorferi infection. Other mouse strains such as Balb/c develop severe carditis but 
mild arthritis, and C57BL/6 develop milder carditis and arthritis (33, 35, 37).  
 Multiple transgenic mouse models have been used to delineate the contribution of 
innate and adaptive immune factors in the development of Lyme borreliosis (35). The 
importance of innate host defense against B. burgdorferi has been demonstrated by the 
use of TLR2-/- and MyD88-/- mouse models as they displayed a severe defect in 
controlling the spirochetal burden in blood and tissues. However, these innate factors 
were not required for disease resolution as these mouse strains showed severe arthritis at 
2 - 4 weeks after B. burgdorferi infection (38-41). The importance of adaptive immune 
responses in Lyme disease pathogenesis has been demonstrated in mouse strains deficient 
in B cells and B and T cells (e.g. µMT-/- and igh-/-, lack B cells but bear T cells; SCID and 
rag1-/-, lack B and T cells). Early studies using these immundeficient mouse strains 
showed that they developed persistent arthritis and carditis and exhibited an elevated 
spirochetal burden in blood and tissues after B. burgdorferi infection for 4 - 8 weeks (42-
45). These studies also showed that spirochetal burden and disease progression can be 
effectively reduced by adoptive transfer of immune mouse serum and B cells, indicating 
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that humoral immunity plays an important role in the control of Lyme borreliosis (43, 
45).  
 Early studies also reported that severity of arthritis decreased overtime as mice 
become adults.  For example, C3H mice at age 3 weeks developed more severe arthritis 
than adult mice (12 weeks) (33, 34). Although all laboratory mice, regardless of the age, 
are susceptible to B. burgdorferi infection, another important factor to take into 
consideration is the plasmid content of the B. burgdorferi isolate used to inoculate those 
mice. Comparison of the plasmid profiles of 19 B. burgdorferi clonal isolates showed that 
the lp25 and lp28-1 were essential to infect mice (46).  Plasmid loss after in vitro 
passages of B. burgdorferi is also associated with decreased virulence in mice (35, 46, 
47).  Laboratory mice can be infected by B. burgdorferi strains by tick bite and a variety 
routes of inoculation, including the intradermal, intraperitoneal, and intravenous routes 
(48-50). Naïve mice are readily infected by the bite of infected ticks (51, 52); however, 
the infectious dose for needle-challenged mice appears to be different among these 
routes. For example, mice can be infected with a dose of 10 or fewer spirochetes per 
mouse via the intradermal route whereas one hundred-fold more spirochetes are needed 
to infect mice via the intraperitoneal route (35, 48). In addition, disease severity has been 
shown to be influenced by the site of inoculation in the skin as mice inoculated in the 
footpad developed higher arthritis and carditis than mice inoculated in the shoulder (53). 
Thus, the use of laboratory mice has provided a useful system for studying Lyme disease 
pathogenesis.  
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Biology of B. burgdorferi 
B. burgdorferi architecture and genome 
 B. burgdorferi is a Gram-negative bacterium belonging to the genus of Borrelia 
species within the phylum of Spirochaetes. These organisms, 20-30 μm in length and 0.2-
0.3 μm in width, have a characteristic wave-like cell morphology with an outer and inner 
membrane surrounding the periplasmic endoflagella (Figure 3) (14). This endoflagella 
also provides a unique mode of motility with both rotational and translational movements 
that allows the spirochete to migrate through host tissues (14, 54). The outer membrane is 
a fluid and fragile bilayer that does not contain LPS. The major lipid constituents in the 
membrane are phosphatidylcholine, phosphatidylglycerol, and cholesterol-glycolipid-rich 
lipid rafts (55, 56). The outer membrane also contains numerous outer-surface 
lipoproteins and few β-barrel outer membrane spanning proteins. The inner membrane is 
rich in integral membrane proteins and different types of specialized transporters (e.g. 
electrochemical, PTS sugar transport system, and ABC transporters) and sits underneath 
a thin peptidoglycan layer (Figure 3) (14). 
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Figure 3.  Morphology and cellular architecture of B. burgdorferi. A) Scanning (left) 
and transmission (right) electron micrographs of B. burgdorferi showing helical shape of 
spirochetes which is primarily imparted by their endoflagella. B) Scanning electron 
micrograph shows two membrane cysts or outer membrane vesicles observed in B. 
burgdorferi (electron micrographs panels are reproduced from (57, 58)). C) Schematic of 
cellular architecture and molecules present in periplasmic space and outer and inner 
membrane of B. burgdorferi. This figure is reproduced from (14).  
 
 B. burgdorferi strains have highly unusual segmented genomes composed of a 
linear chromosome of approximately 910 kb and numerous linear and circular plasmids 
(in the 5-56 kb size range) totaling approximately 610 kb (59, 60). Genomic analysis of 
B. burgdorferi strains have shown that the chromosome carries the majority of 
housekeeping genes that encode metabolic enzymes while plasmids largely carry genes 
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that encode surface lipoproteins. With the only exception of cp26 that appear to encode 
functions critical for B. burgdorferi survival, the rest of the circular and linear plasmids 
are not required for in vitro growth of spirochetes (61, 62). Plasmid cp26 carries genes 
that encode several nucleotide metabolic enzymes, peptide, purine, chitobiose, and 
glucose transporters, and a telomere resolvase that is required for replication of the linear 
chromosome and plasmids (62, 63). Plasmid cp26 also encode the ospC gene that is 
important for mouse infectivity (49, 64, 65).  
Regulation of outer membrane proteins for mammalian infection 
 As mentioned above, B. burgdorferi is maintained in nature by a complex life 
cycle involving ticks and small mammals. To support this lifestyle, B. burgdorferi adapts 
to these two markedly distinct host environments by coordinately regulating the 
expression of numerous genes. Dr. Frank Yang’s lab and other groups have demonstrated 
the Rrp2-RpoN-RpoS canonical pathway (also called the σ54-σS sigma factor cascade, 
Figure 4) plays a central role in modulating gene expression during different phases of 
the enzootic cycle (66-68). In this pathway, the two-component response regulator Rrp2 
directly activates the alternative sigma factor RpoN (σ54 or σN), which in turn is required 
for transcription of the rpoS (66, 67). The alternative sigma factor RpoS (σS) then acts as 
global regulator and can activate transcription of approximately 145 genes that appear to 
be important for transmission or are involved during different stages of mammalian 
infection. Many of these genes encode surface lipoproteins such as OspC, DbpBA, 
BBK32, and BBA64 that are important for virulence within the mammalian host (69). 
Conversely, this pathway represses important tick phase-specific genes such as ospA 
(67). Evidence has accumulated that rpoS expression is upregulated by several 
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environmental cues when nymphal ticks start feeding on mammals (70). These 
environmental cues lead to the activation of RpoS that subsequently leads to upregulation 
of ospC and other genes required for host adaptation. Consistent with this notion, rpoS or 
ospC mutants are incapable of establishing infection in mammals. Similar phenotype is 
observed for B. burgdoferi strains lacking Rrp2 or RpoN since neither of these mutants 
can establish infection in the mammalian host (69, 71, 72). Recently another 
transcriptional regulator termed BosR was shown to bind the rpoS promoter region at 
three different sites and induce the expression ospC and dbpAB in an RpoN-RpoS 
dependent manner (73, 74). In fact, inactivation of bosR in B. burgdorferi also resulted in 
a noninfectious phenotype in mice (73, 75). These findings further support that the 
RpoN-RpoS pathway is essential for B. burgdorferi to establish mammalian infection. 
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Figure 4. The Rrp2-RpoN-RpoS pathway plays a central role in the regulation of B. 
burgdorferi outer membrane proteins during mammalian infection. It has been 
proposed that activation of the response regulator Rrp2 occurs by several environmental 
signals after nymphal ticks start feeding on mammals. An increase in temperature (from 
25°C to 37°C) and pH (from 6.8 to 7.4) are some environmental cues that appear to 
activate this pathway as spirochetes transtions from ticks to mammals. These signals lead 
to phosphorylation of Rrp2 to initiate transcription of rpoS through the alternative sigma 
factor RpoN (σN), which also interacts with RNA polymerase (RNAP). RpoS (σS) in turn 
induces the expression of genes such as ospC that are important for spirochetes to infect 
mammals while repressing the expression of genes such as ospA that are important for 
tick colonization. BosR also plays a role in the initiation of transcription of rpoS and has 
been proposed to form a trimeric complex with phosphorylated Rrp2 and RpoN that sits 
on the rpoS promoter region, but the exact interaction of these proteins has not been 
elucidated.  
 
B. burgdorferi traits during infection in mammals.  
 Unlike most classical Gram-negative bacterial pathogens, B. burgdorferi does not 
produce LPS or toxins or have specialized secretion and translocation systems (14). 
Instead, the B. burgdorferi genome encode a large number of surface lipoproteins that 
allow spirochetes to adapt, adhere, invade, and persist in mammalian tissues. These 
surface proteins can also trigger innate and adaptive inflammatory reactions at different 
stages of mammalian infection (76). After spirochetes are deposited into the host skin by 
a tick bite, they replicate locally in the dermis and then disseminates to tissues by 
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different means (77, 78). B. burgdorferi utilizes its endoflagella to migrate locally 
through connective tissue or hematogenously to distant organs from the initial site of 
infection (76-78). Intravital microscopy studies have characterized motility and 
dissemination patterns of single live fluorescent spirochetes within the mouse’s skin, 
vasculature, and organs (50, 79). Spirochetes can easily be observed in living mouse skin 
for up to one month after subcutaneous inoculation. Spirochetes are predominantly found 
in the perivascular region of the mouse dermis where they bind to and translocate through 
ECM constituents such as type I collagen to access small vessels for hematogenous 
dissemination (76, 79). Once in the circulation, spirochetes frequently adhere to the 
vascular endothelium and migrate up (against the blood flow) and down the blood vessel 
surface to extravasate into tissues (50). In addition, Drs. Nicole Bamgaurth and Stephen 
Barthold and coworkers have recently proposed that B. burgdorferi can actively 
disseminate through the lymphatic system as live spirochetes are frequently re-isolated 
and detected in draining lymph nodes proximal to the inoculation site prior to the 
detection of spirochetes in other tissues (80, 81). Furthermore, B. burgdorferi strains 
lacking one of the major endoflagellar filaments such as FlaB (e.g. flaB mutant) are 
nonmotile and cannot survive at the skin site of inoculation of mice (82), a finding that 
clearly illustrates that the endoflangella is essential for spirochetes to disseminate and 
establish infection in  mammals. 
 To successfully adhere and colonize tissues in mammals, B. burgdorgferi deploys 
a variety of surface proteins that mediate attachment with host cells and components of 
the ECM (83). These B. burgdorferi adhesins bind to a variety of ligands in tissues, 
including fibronectin, glycosaminoglycans, proteoglycan decorin, collagen, laminin, and 
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integrins (83, 84). To date, there are 5 fibronectin binding proteins (BBK32, RevA/B, 
BB0347, and CRASP-1), 3 glycosaminoglycan binding proteins (BBK32, DbpAB, and 
Bgp), 1 decorin binding protein (DbpAB), 1 collagen binding protein (CRASP-1), 2 
laminin binding proteins (CRASP-1 and CRASP-2), and 4 integrin binding proteins 
(BBK32, P66, BBB07, BB0172), all identified in B. burgdorferi using mostly in vitro 
systems and in some cases in vivo (79, 84). Among these adhesins, P66 has been shown 
to be essential for infection of immunocompetent mice (ID50 was greater than 108 
spirochetes). The p66 mutant was rapidly cleared within the first 48 h in these mice and 
could not even establish infection in TLR2-/- and q-/- mice (85). The dbpAB mutant 
showed a significant defect in infectivity in immunocompetent mice during the early 
phase of infection that was dependent on acquired immunity (84, 86, 87). The bbk32 
mutant showed mild attenuation of infectivity in mice and a significant decrease in 
vascular adhesion in vivo (79). In contrast, the Bgp mutant remained infectious in 
immunodeficient mice (88). Although these adhesins exhibit overlapping and redundant 
interactions with more than one component of the ECM, they likely have distinct roles in 
homing of B. burgdorferi to different tissue compartments throughout the course of 
mammalian infection. Thus, adhesion of B. burgdorferi to host cells and ECM 
components is an important first step in the establishment of infection. 
 Previous studies have proposed that B. burgdorferi utilizes host proteases such as 
plasmin to break down components of the ECM as a mechanism to promote invasiveness 
of spirochetes in tissues. B. burgdorferi has the ability to bind to host plasminogen using 
several known outer membrane proteins, such as OspC, OspA, ErpA, ErpC, ErpP, 
CRASP-1, CRASP-2, and BBA70 proteins (84, 89). This surface-bound plasminogen can 
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be converted into the serine protease plasmin by host-derived plasminogen activators to 
enhance the ability of spirochetes to penetrate endothelial cells monolayers (90, 91). 
However, the contribution and functional relevance of this surface-bound plasmin during 
spirochetal infection is not well understood. In studies using plasminogen deficient mice, 
plasmin appeared to be important in enhancing spirochetemia during dissemination of B. 
burgdorferi but did not play a role in establishing infection in distant tissues (92). Thus, 
binding of plasminogen may be important during the early stage of infection in mice 
when spirochetes migrate from the dermis into the vasculature for hematogenous 
dissemination. 
Role of OspC during Lyme borreliosis 
 OspC is a 22 kDa immunodominant lipoprotein that is primarily alpha helical in 
structure with five parallel α-helices connected by intervening loops (93, 94). OspC is 
highly expressed during early infection and can elicit protective antibody responses 
against B. burgdorferi infection in the mammalian host. OspC is also highly polymorphic 
in sequence among B. burgdorferi strains with approximately 28 different ospC 
genotypes (95). Because of this OspC diversity among strains, the antibody response 
elicited during early infection appears to be OspC-type specific (95). In addition, B. 
burgdorferi strains producing certain OspC-types are associated with invasive infections 
in patients and experimentally infected animals (96, 97). 
 To date, the precise function of OspC still remains elusive. Several lines of 
evidence suggest that OspC is a major virulence factor that is required for the 
establishment of mammalian infection (65, 98). OspC-deficient spirochetes are rapidly 
cleared from mammalian hosts (64, 99). Also, the structural similarity of OspC to the 
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ligand-binding domain of the aspartate receptor from Salmonella enterica serotype 
Typhimurium suggests that OspC could bind to distinct ligands during mammalian infection 
(93). Our studies in part I of this dissertation evaluated the role of OspC in the protection 
of spirochetes against innate host factors in vivo and in vitro. Studies on the role of OspC 
during mammalian infection are discussed in more detail in part I of this dissertation. 
Immune evasion strategies  
 B. burgdorferi has evolved strategies to escape immune clearance and persist 
within infected hosts for several months or years. The two main strategies utilized for 
immune evasion are antigenic variation and complement resistance. Other observations 
of spirochetal persistence in the host include the following: homing of spirochetes in 
protective niches such as collagen bundles; changes in B. burgdorferi gene expression in 
response to the stage and site of infection; and formation of outer membrane vesicles or 
cysts as a strategy of spirochetal survival during antibiotic therapy (76, 100-102). For the 
purpose of this literature review, I have focused on the immune evasion strategies that are 
well understood.  
Evasion of humoral immunity 
 Accumulated evidence has shown that B cell activation and antibody responses 
play an important role in the control of B. burgdorferi burden and disease resolution 
during infection in immunocompetent mice (35, 43, 45, 80). However, these wild-type 
mice remain persistently infected for months after the initial challenge because humoral 
immunity against B. burgdorferi appears to lack a robust functional adaptive memory 
response (35, 80, 103). In fact, mice are commonly re-infected by tick-transmitted B. 
burgdorferi in nature (52, 104). One possible explanation why B. burgdorferi escape the 
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humoral response and persist in the mammalian host is due to variations on the antigenic 
surface of spirochetes. The plasmid lp28-1 of B. burgdorferi contains a vlsE locus that 
codes for a surface lipoprotein named VlsE (102). The vlsE gene is flanked by 15 silent 
cassettes upstream that undergo random recombination with the vlsE central cassette, 
leading to gene conversion events and variations in the antigenic properties of VlsE (76, 
102). It is well-accepted that the vlsE locus undergoes extensive recombination events 
over the course of mammalian infection that can be detected in B. burgdorferi reisolates 
as early as 4 days post-infection in mice. The vlsE locus is required for B. burgdorferi to 
establish infection and reinfection in immunocompetent mice (105, 106). In contrast, vlsE 
mutants can infect and persist in SCID mice (105-107) but cannot establish infection in 
passively immunized SCID mice with Borrelia specific immune sera (106). Together, 
these findings have shown that vlsE permits the evasion of host humoral responses during 
B. burgdorferi infection.  
 An alternate explanation why B. burgdorferi evade humoral immunity may rely 
on the ability of this pathogen to alter an effective memory B cell response during 
infection (80). Recent studies have proposed that the lack of functional T cell-dependent 
B cell responses is due to the presence of short-lived and low-affinity antibodies during 
active B. burgdorferi infection in mice (80, 103).  These T cell dependent antibodies 
begin to decline after 6 weeks of infection when spirochetes or antigens are still detected 
in multiple mouse tissues (43, 103). Thus, these findings suggest that B. burgdorferi 
modulate the quality of T cell dependent humoral responses during active infection, 
allowing some spirochetes to persist and escape immune clearance.  
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Resistance to complement   
 The complement system, an arm of the innate immune system, is a complex 
cascade of plasma proteins and membrane associated proteins involved in the early 
detection of invading pathogens. Complement activation occurs through three different 
pathways: the classical, lectin, and alternative (108). All three pathways converge at the 
level of C3 convertases, which in turn are responsible for generating the main effector 
functions of the complement system such as the secretion of peptide mediators of 
inflammation (C3a/C5a), formation of membrane attack complex (e.g. C5b-9) for 
pathogen lysis, and opsonization of pathogens (e.g. C3b) (108). Previous studies have 
proposed that B. burgdorferi resist complement mediated killing through the recruitment 
of host complement regulators, interaction with tick salivary proteins, and evasion of the 
lytic alternative pathway (109). In vitro studies also showed that B. burgdorferi is able to 
grow in the presence of human sera, a feature that was correlated with the expression of 
complement regulator acquiring surface proteins (CRASPs) in spirochetes (76). To date, 
there are 5 CRASPs (CRASP-1 to 5) proteins identified in B. burgdorferi (84). These 
proteins bind to the complement regulator Factor H and its related proteins, which 
enables spirochetes to reduce activation of the complement alternative pathway which in 
turn prevents the deposition of C3b and formation of membrane attack complex on the 
cell surface (109). Another mechanism by which B. burgdorferi evades complement 
mediated killing is by binding to tick salivary proteins. B. burgdorferi OspC binds a tick 
salivary protein named Salp15 to protect spirochetes from complement mediated killing 
via the alternative pathway (110, 111). Recently, another group showed that B. 
burgdorferi co-opts another tick salivary protein named TSLP1 to protect spirochetes 
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from complement mediated killing via the lectin pathway (109). The third proposed 
mechanism that B. burgdorferi uses to evade complement is inherent to changes in its 
outer membrane composition that sterically inhibits the lytic activity of the membrane 
attack complex (109). In vivo studies using mice deficient in C5 provided further 
evidence that clearance of B. burgdorferi does not require activation of the alternative 
pathway (112). In contrast, studies using mice deficient in C3 (113, 114) suggest that 
C3b-mediated phagocytosis plays a role in controlling spirochetal burden in these mice.    
Innate cellular response against B. burgdorferi 
 
 Innate cellular responses play a central role in the recognition and clearance of B. 
burgdorferi in infected tissues from humans and animal models (35, 114). 
Histopathological EM lesions from infected patients have demonstrated that cellular 
infiltration in the skin samples is predominantly composed of macrophages/monocytes, 
DCs and T cells, few neutrophils, and rare plasma cells (115). Neutrophils and 
macrophages are also commonly detected in the skin within the first 3 days after B. 
burgdorferi challenge in the rabbit model of Lyme borreliosis (116). Although mice do 
not develop EM lesions, many studies have also demonstrated that 
macrophages/monocytes and neutrophils commonly infiltrate joints and hearts during 
early and disseminated stages of B. burgdorferi infection (35). During the first 2-3 weeks 
(acute phase) of infection, macrophages/monocytes are the dominant cell infiltrate 
driving the inflammatory response in the heart, and neutrophils are the predominant cell 
infiltrate associated with joint inflammation in wild-type mice (35, 114). These 
observations provided the first evidence that different mechanisms may be involved in 
the pathogenesis and pathology of Lyme borreliosis in these two organs (114). 
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Spirochetes are found within all regions of the heart and joints, but as the phagocyte 
responses evolve, spirochetes are restricted to specific sites where they can persist in the 
heart (e.g. aortic wall and base of the heart) and joints (e.g. tendons and ligaments) (33, 
35, 77). At the acute stage, spirochetes are also commonly detected in subcutaneous 
tissue which is slightly infiltrated with neutrophils and macrophages (35). Thus, 
phagocytes are an essential component in the early host defense against B. burgdorferi in 
vivo. 
Recognition of B. burgdorferi by macrophages and neutrophils 
 The recognition of B. burgdorferi is a complex process involving several PRRs 
that initiate an innate immune response against invading spirochetes (114). The outer 
membrane of B. burgdorferi is decorated by numerous surface lipoproteins anchored to 
the membrane lipid bilayer via tripalmitoyl-S-glyceryl-cysteine (Pam3Cys) modifications 
(117). This is an important ligand for the recognition of B. burgdorferi by Toll-like 
receptor (TLR) 2/1 heterodimers on the phagocyte surface (118, 119). TLR2 then signals 
through the MyD88-dependent pathway leading to the activation of NF-κB that 
subsequently results in the production of cytokines (e.g. TNF-α, IL-1β, IL-6, IL-10, and 
IFN-γ), chemokines (e.g. IL-8 and CCL2), and adhesion molecules (e.g. ICAMs) (114, 
119, 120). Although the interaction of spirochetal lipoproteins with the TLR2/1 receptor 
has been primarily focused on monocytes and macrophages, these lipoproteins also serve 
as TLR2 ligands for human neutrophils as this TLR receptor is commonly present on the 
surface of these cells (121). In addition, CD14 is a glycosylphosphatidylinositol (GPI)-
anchored membrane protein expressed on phagocytes (122) that serves as a co-receptor 
for TLR2 to facilitate the activation of the innate immune response against B. 
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burgdorferi. The loss of either TLR2 or CD14 in mice leads to a defective innate immune 
response against B. burgdorferi as infected TLR2-/- and CD14-/- mice displayed a severe 
defect in the control of spirochetes in tissues when compared to controls (41, 122). In 
contrast, both TLR2-/- and CD14-/- mice showed an increased severity of arthritis (41, 
122) indicating that other regulatory pathways induced by lipoproteins contribute to the 
inflammatory responses in infected tissues.  
 In addition, several other TLR members and Nucleotide Oligomerization Domain-
like receptors (NLR) have been linked to the recognition of B. burgdorferi. TLR5, a cell 
surface receptor for bacterial flagellin, has been shown to play a role in the recognition of 
B. burgdorferi products and induction of cytokines and chemokines in murine 
macrophages and human monocytes (123, 124). TLR2 may also cooperates with other 
endosomal TLRs (e.g.TLR7/8/9) in the induction of cytokines and/or type I interferons 
(e.g. IFN-α /-β) in human monocytes and PBMCs (124-126). Several lines of evidence 
suggest that these endosomal TLRs can sense B. burgdorferi products such as RNA and 
DNA after phagocytosis (125-127), which leads to the activation of NF-κB as well as 
IRF7 and IRF3 MyD88-independent pathways. 
 Intracellular NLR receptors such as Nod2 and NLRP3 inflammasome have been 
reported to participate in the recognition of B. burgdorferi, but the mechanism for how 
these receptors are activated is not well understood. Studies using Nod1 or Nod2 
deficient PBMCs suggest that Nod2 played a major role in the recognition of spirochetes, 
as the production of cytokines was markedly lower in B. burgdorferi-stimulated cells 
from individuals with non-functional Nod2 when compared to healthy controls. However, 
Nod2-/- mice displayed much higher inflammation in the heart and joints during infection 
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than controls indicating that Nod2 is involved in down-regulating inflammation in Lyme 
borreliosis (128, 129). NLRP3 multi-protein complex belong to the NLRP family of 
inflammasomes that are activated by a unique set of microbial and endogenous ligands 
that triggers the assembly of this complex. This activated complex then induces 
maturation of inflammatory cytokines IL-1β and IL-18 through the action of caspase-1 
(130). To date, there is limited information on which B. burgdorferi ligands activate the 
inflammasome; however, activation of NLRP3 complex is involved in the production of 
IL-1β in B. burgdorferi-stimulated murine macrophages (131). This finding was 
illustrated by the marked reduction of IL-1β levels in stimulated cells from mice deficient 
in NLRP3, the adaptor molecule ASC, or caspase-1 when compared to control mice 
(131). Caspase-1 dependent maturation of pro-IL-1β (inactive) appeared to regulate this 
reduced production of IL-1β in these cells (131). Despite the presence of 
proinflammatory cytokines that are the result of Nod2 and NLRP3 activation, the role of 
these NLR receptors in host defense and disease during Lyme borreliosis has not been 
fully characterized.  
Phagocytosis of B. burgdorferi 
 Macrophages, monocytes, and neutrophils can also efficiently recognize and 
phagocytose B. burgdorferi spirochetes in large numbers (132, 133). Early studies into 
the kinetics of phagocytosis showed that spirochetes are internalized in human and 
murine macrophages as early as 5 min after incubation and are progressively detected 
within the cell’s lysosomal compartments after 60 - 180 min incubation (132-135). 
Phagocytosis of spirochetes occurs through at least three mechanisms such as coiling 
phagocytosis, opsonic-mediated phagocytosis (132, 136), and conventional phagocytosis 
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(137, 138) (Figure 5). Phagocytic uptake of Borrelia by macrophages via coiling 
phagocytosis is characterized by the formation of actin-rich filopodial protrusions that 
capture and enwrap spirochetes, which ultimately are converted into coiling pseudopods 
inside the cell (139). The molecular mechanism of actin polymerization and 
rearrangement in macrophages during coiling phagocytosis of Borrelia is complex and 
involves several actin nucleation (e.g. mDia1 Arp2/3 complex, WASP, and FMNL1-
formin) and regulatory factors (e.g. Daam1 CDC42, Rac1, and Rho GTPases) (139, 140). 
Following internalization of spirochetes, they are degraded within the phagolysosomes 
(133, 139).  In addition, MyD88-dependent PI3K signaling appeared to play a role in the 
formation of this filopodium for phagocytosis of Borrelia by murine macrophages (141). 
Furthermore, inhibition of PI3K kinase in murine macrophages showed that phagocytosis 
was markedly reduced in MyD88 deficient cells to a similar level as controls (141), 
suggesting that the TLR2/MyD88/PI3K signaling pathway may be involved in the 
regulation of coiling phagocytosis of spirochetes.  
 Opsonic phagocytosis is a process mediated by the deposition of IgG antibodies 
on the surface of B. burgdorferi that target them for recognition and internalization by Fc 
receptors on phagocytes (132, 142). Macrophages have shown to be able to ingest 
spirochetes avidly with or without antibody-mediated opsonization (132, 143). In 
contrast, opzonization of spirochetes appeared to be required for monocytes and 
neutrophils to efficiently internalize them (142, 143). The Fc receptor has been proposed 
to play a role in the ingestion of spirochetes during the early stage of Lyme disease as 
immune complexes containing spirochetal antigens were commonly detected in serum 
samples in patients with EM lesions (142, 144). Studies using mice deficient in the Fc 
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common gamma chain (FcRγ−/− mice) displayed higher bacterial burden in urinary 
bladders and arthritis severity than infected control mice at early time points of infection 
(145).  This defective clearance of spirochetes during early infection suggests the 
possibility of the involvement of at least two defects in antimicrobial defenses, as FcRγ−/− 
mice are defective in macrophage-mediated opsonic phagocytosis and antibody-
dependent NK cell-mediated cytotoxicity (146).  
 In conventional phagocytosis, Borrelia ligands are directly recognized by 
phagocytic receptors which are the main drivers in the engulfment of spirochetes by 
macrophages (125). Several phagocytic receptors have been reported to mediate this 
process that is discussed in the Results section below. 
 
 
Figure 5. Proposed mechanisms of phagocytosis of B. burgdorferi. A) Opsonic 
phagocytosis primarily involves the interaction of Fc receptors with opsonic antibodies 
bound to the surface of spirochetes leading to internalization of this organism. 
Additionally, complement receptor 3 (CR3 or CD11b/CD18) can also participate in the 
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uptake of spirochetes in the presence or absence of complement-derived opsonins, such 
as C3b and C3bi. B) Conventional phagocytosis involves the interaction of different 
phagocytic receptors (e.g. CR3 and scavenger receptors) that specifically recognize 
ligands on the surface of spirochetes, leading to the formation of pseudopod cups that 
move around the organisms. TLR2/1 heterodimers, CD14 receptors and other PRRs also 
contribute in the recognition of spirochetes and appear to have a positive role on 
conventional phagocytosis. C) Coiling phagocytosis involved the formation of unilateral 
F-actin filopodial protrusions which enwraps the spirochete and pulls it inside the 
phagocyte. TLR signaling can also occur from the phagosome after spirochetes are 
degraded in this compartment (schematic drawing of phagocytosis is reproduced from 
(125)). Following recognition of spirochetes by TLRs, phagocytes signal via MyD88-
dependent or -independent pathways to generate inflammatory mediators (e.g. cytokines 
and type I IFN). 
 
Antimicrobial killing mechanisms of phagocytes. 
 In order to survive in the mammalian host, B. burgdorferi must be able to 
overcome a variety of oxidative and non-oxidative stressors produced by professional 
phagocytes. Neutrophils can kill spirochetes either in the intracellular compartments or 
extracellularly by both oxidative and non-oxidative killing mechanisms (135, 143, 147-
149). Neutrophils have been shown to ingest opsonized spirochetes more effectively than 
nonopsonized organisms (148), which eventually are killed within the phagolysosome. 
However, it is thought that the majority of spirochete killing by neutrophils occurs 
outside the cell (143). In vitro studies have shown that B. burgdorferi and the surface 
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lipoprotein OspA activate neutrophils to produce reactive oxygen species and nitrate 
species (150, 151). In fact, B. burgdorferi is susceptible to killing by both oxidative and 
nitrosative stresses, likely because its genome encodes a small number of antioxidant 
enzymes that defend against these stresses (152, 153). Neutrophils also produce granules 
filled with proteases and proinflammatory proteins that can kill spirochetes either in the 
phagolysosome or in the extracellular milieu. Among antibacterial granules produced by 
neutrophils, B. burgdorferi have been shown to be highly susceptible to elastase, LL-37, 
BPI protein, and human neutrophil peptide-1 (148, 154). Ongoing stimulation of 
neutrophils can also lead to the release of neutrophil extracellular traps, which are 
composed of DNA, antimicrobial histones, and granular proteases, that can capture and 
kill B. burgdorferi (149). 
 Macrophages are also critical in the clearance of B. burgdorferi during infection 
as they readily kill spirochetes by the action of proteases and oxidative stress (134, 143). 
Furthermore, opsonization of spirochetes has been shown to enhance killing of 
spirochetes mediated by both reactive oxygen and nitrogen species inside the cell (155). 
Although extracellular killing of spirochetes by macrophages can also occur, most of the 
killing of spirochetes by macrophages takes place in the phagolysosome vacuole (134, 
155). Despite the susceptibility of B. burgdorferi to oxidative and nitrosative stress in 
vitro, no differences in spirochetal burden are observed  in mice lacking either the 
subunits of the NADPH oxidase complex (Gp91phox-/- and Ncf1-/-) (156) or the inducible 
nitric oxide synthase (iNOS-/-) (157)  when compared to wild-type mice. Thus, these 
findings raise the possibility that lacking the NADPH oxidase complex or inducible nitric 
oxide synthase could compensate for one another to control spirochetal burden in vivo or 
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have a compensatory role in other antimicrobial mechanisms during spirochetal infection. 
Another possibility is that B. burgdorferi may exploit specific tissue milieus (114) and/or 
host metabolites such as pyruvate (153) to resist oxidative stress. 
Dendritic cells  
 Dendritic cells are a group of highly specialized antigen presenting cells whose 
primary tasks are to recognize, ingest, process, and present antigens to T cells in 
lymphoid tissues. Unlike neutrophils and macrophages, their major function is not to 
ingest and kill bacteria but to alert and activate other effector cells of the innate and 
adaptive immune systems (158). Traditionally, DCs are classified based on their 
phenotypic and functional characteristics into four major groups such as epidermal 
Langerhans cells (LCs), conventional DCs, monocytoid DCs, and plasmacytoid DCs 
(158). Histologic and electron microscopy studies have demonstrated that DCs are 
commonly present in the dermis and spirochetes can be observed within vacuoles in LCs 
in the epidermis of EM lesions of patients infected with Lyme borreliosis (24, 159). 
Dermal DCs from EM lesions were further characterized as plasmacytoid and 
monocytoid DCs (115) and have been shown to have a higher ability to engulf 
spirochetes than LCs in vitro (160).  B. burgdorferi has been shown to induce the surface 
expression of TLR1 and TLR2 in dermal DCs from EM lesions, suggesting that TLR2/1 
heterodimer are important in the recognition of spirochetes and development of an 
inflammatory response in the skin (115). However other TLRs may be involved in the 
recognition of spirochetes by DCs since they can express all TLRs with the exception of 
TLR9 (115, 161). DCs and LCs incubated with spirochetes in vitro showed that they were 
also able to process and present spirochetal antigens via MHC class II molecules to T 
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helper cells (160). B. burgdorferi-pulsed DCs incubated with T and B cells mixtures in 
vitro can also induce the production of antibodies against Borrelia antigens (e.g. OspA) 
(160, 162). Another mechanism for how DCs can present Borrelia lipid antigens on the 
cell surface to interact with T cells or NKT cells is via the group I of CD1 molecules 
(163). Furthermore, in vivo studies showed that CD1d-/- mice had defective spirochetal 
clearance in tissues (164). Thus, together these data indicate that DCs contribute to the 
initial innate immune response in the skin during Lyme borreliosis. 
Natural Killer cells 
 NK cells are large granular lymphocytes of the innate immune system that have 
the ability to kill abnormal cells and pathogens as well as to modulate inflammatory 
responses by secreting cytokines and engaging interactions with different immune cells, 
including DCs, macrophages, T cells, and endothelial cells (165). In Lyme disease, the 
role of NK cells during B. burgdorferi infection is not fully characterized. IFN-γ 
producing NK cells have been shown to be increased in the synovial fluid of infected 
patients with either antibiotic-responsive or antibiotic-refractory Lyme arthritis (166), 
suggesting that these cells could contribute to both spirochetal killing in patients without 
arthritis and in joint inflammation in patients with arthritis. NK cell cytotoxic activities 
against tumor cells in vitro have been shown to be markedly reduced in peripheral blood 
lymphocyte fractions from untreated patients with EM lesions and from patients in the 
chronic active stage of Lyme disease (167). This reduction in NK cell activity appeared 
to be mediated by the presence of viable spirochetes via an unknown mechanism (167). 
In contrast, antibody depletion studies with murine models of Lyme disease have shown 
that NK cells were not necessary for the development of arthritis (168, 169) and were not 
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involved in the control of bacterial burden in joints or the ability to prevent dissemination 
of spirochetes to tissues during infection (169). In addition, murine NK cells produce 
IFN-γ when co-incubated with B. burgdorferi-primed or OspA/B-primed macrophages 
(170). This observation suggests that NK cells could play a role in the activation of 
phagocytes at particular points of B. burgdorferi infection in mice. 
Summary of introduction 
 B. burgdorferi is a tick-transmitted pathogen that has shown a great ability to 
survive and adapt to different host environments and to cause invasive and persistent 
infections in humans and other mammals. Once inoculated in the dermal tissue, this 
extracellular pathogen rapidly replicates at the site of inoculation and disseminates to 
multiple organs, causing disease (14). The outer membrane of B. burgdorferi is highly 
abundant with surface lipoproteins which play roles at distinct stages of mammalian 
infection (76). OspC expression has been shown to play an important role in the initial 
stage of colonization of tissues in the murine model of Lyme borreliosis. Other surface 
lipoproteins mediate attachment to different ECM components and host cells, resistance 
to complemement, and variation of antigens, which allow the spirochete to invade tissues 
and evade host defenses during disseminated infection (76, 84). At the same time, these 
surface lipoproteins stimulate the activation of tissue-specific resident and innate and 
adaptive effector cells at the site of infection. This leads to the production of 
inflammatory mediators and recruitment of leukocytes that are associated with the acute 
inflammatory lesions in humans and experimental animal models (18, 35). Studies using 
mouse models deficient in different components of the innate and adaptive immune 
systems have demonstrated that both arms of the immune system are required for 
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activation of host defenses against B. burgdorferi infection (114). Although B. 
burgdorferi burden is effectively controlled by innate and adaptive immunities in the 
mouse model of Lyme borreliosis, these animals can remain persistently infected for 
months to over one year as non-cultivable spirochetes are detected in collagen bundles in 
various tissues with minimal histopathological evidence of inflammation (35). 
Persistence of B. burgdorferi infection using different experimental animal models of 
Lyme disease is an area of active investigation. 
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CHAPTER II: RESEARCH GOALS 
The role of B. burgdorferi OspC in protection against phagocytes  
 The B. burgdorferi genome encodes a large number of surface lipoproteins, many 
of which are expressed during mammalian infection (14, 67). One of these lipoproteins is 
the major outer surface lipoprotein C whose production is induced within infected 
nymphal ticks during feeding (49, 171). OspC remains produced during the early phase 
of infection and is highly immunogenic in mice (172, 173). As one of the strategies to 
evade host humoral responses, spirochetes downregulate OspC production in response to 
anti-OspC antibodies within 2-3 weeks after infection in mice (174, 175). OspC has 
shown to be required for B. burgdorferi to establish infection in mammals (49, 176). 
Infectivity studies demonstrate that the ospC mutant cannot establish infection in 
immunocompetent and SCID mice (lacking B and T cells) when inoculated at a dose of 
103 – 105 spirochetes per mouse (49, 65, 98, 177). The ospC mutant is cleared within the 
first 48 h of infection in the murine host (64), suggesting a protective role of surface 
lipoproteins against innate defenses. OspC also has been proposed to play roles in 
promoting survival and/or dissemination of spirochetes within the mammalian host. For 
example, OspC binds to a tick salivary protein, Salp15, which can protect spirochetes 
from complement- and antibody- mediated killing (111, 178). OspC has shown to bind 
host plasminogen (89, 179), and this phenotype correlates with invasiveness of 
spirochetes within mice (180). In addition, constitutive expression of heterologous 
lipoproteins in the ospC mutant has shown to restore infection in SCID mice, suggesting 
that OspC may have a non-specific structural role for B. burgdorferi (176, 177). On the 
other hand, another study suggested that the residues within the putative ligand-binding 
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domain are important for OspC function (179). Despite all research efforts, the precise 
biological function of OspC during infection remains unclear. 
 Innate immunity represents the first line of defense against B. burgdorferi 
infection in mammals (125, 143). Professional phagocytes, such as 
monocytes/macrophages and neutrophils, are among the first innate cells that spirochetes 
encounter during early infection in mammals (148, 181, 182). These phagocytes are 
essential in controlling the spirochetal burden and directing the development of adaptive 
immune responses during infection in the murine host (31, 32, 39). Phagocyte recognition 
of spirochetes is initiated by multiple TLR receptors, including TLR2/1 heterodimers, 
which signal through the adaptor molecule Myeloid differentiation primary response 88 
(MyD88) (125). In murine models, deficiency of MyD88 results in markedly elevated B. 
burgdorferi burdens in tissues when compared to infected wild-type mice (38, 39). 
However, the ospC mutant remained non-infectious in MyD88-/- mice (183). Despite the 
understanding of the immune mediators that modulate host defense and inflammation in 
the murine model of Lyme borreliosis, the role of professional phagocytes and other 
innate cells in the clearance of the ospC mutant has not been examined.   
 In our studies, we investigated the role OspC for protection of spirochetes against 
innate host factors using a genetic, antibody-mediated, and pharmacological approach. 
We showed that the ospC mutant was not capable to establish infection in NODSCID-
IL2rγnull and anti-Ly6G-treated SCID mice, suggesting that NK cells, lytic complement, and 
neutrophils were not critical in the clearance of the ospC mutant in vivo. However, our 
results showed that F4/80+ phagocytes at the skin-site of inoculation are important in the 
clearance of the ospC mutant in clodronate-treated SCID mice. We further showed that 
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OspC played a role for B. burgdorferi in macrophage phagocytosis by reducing the 
uptake of GFP-expressing wild-type spirochetes in these phagocytes. Together our 
findings suggest that OspC protects B. burgdorferi strains from F4/80+ phagocytes by 
promoting spirochete’s evasion of these innate cells during early infection in mammals. 
The role of elongation factor EF-Tu during Lyme borreliosis 
 B. burgdorferi expresses a large number of outer surface lipoproteins that are the 
major interface in interacting with host environments. Accumulated evidence has 
demonstrated that these surface proteins play a central role for the successful 
maintenance of B. burgdorferi within the enzootic life cycle involving Ixodes ticks and 
mammals (14, 184, 185). B. burgdorferi must adapt to these two markedly different host 
environments by coordinately altering its gene expression and antigen profile (67, 186, 
187). A well-characterized example is the reciprocal regulation of the outer surface 
lipoproteins OspA and OspC (67, 188) when B. burgdorferi transitions between ticks and 
mammals. Spirochetes also use many of these surface lipoproteins during infection to 
bind a variety of ECM components, proteases and complement regulators such as 
plasminogen and factor H, and host cell types (83, 84). Some of these surface proteins 
also trigger an immune response and have been selected as serodiagnostic markers and 
potential vaccine candidates (189-191). 
 While much work on surface proteins have focused on lipoproteins, proteome 
analysis has recently described that known cytosolic proteins of B. burgdorferi are 
associated with membrane fractions in variable amounts (192, 193). One such protein is 
enolase, an enzyme that catalyzes the conversion of 2-phosphoglycerate into 
phosphoenolpyruvate for glycolysis in B. burgdorferi (60), that has also been shown to 
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associate with the cell surface and be present in outer membrane vesicles of spirochetes 
(193-195). Although the mechanism of how enolase is transported to the surface remains 
unclear, several reports have shown that enolase binds to plasminogen/plasmin in vitro, 
suggesting a role in assisting spirochetes to disseminate during mammalian infection. B. 
burgdorferi enolase also triggered an antibody response that reduced tick acquisition of 
spirochetes from mice (195). Another cytoplasmic protein that can be found on the 
surface of bacteria is the elongation factor Tu (EF-Tu). Surface EF-Tu from pathogenic 
bacteria has shown to perform functions involved in adhesion, invasion, and modulation 
of the host immune system (196, 197). For example, surface EF-Tu serves as fibronectin 
binding protein for Mycoplasma pneumoniae, which may facilitates the interaction of this 
pathogen with extracellular matrix (198). Surface EF-Tu from Leptospira interrogans, 
Streptococcus pneumoniae, and Pseudomonas aureginosa binds to the complement 
regulators factor H and plasminogen and may have roles in immune evasion and tissue 
invasion (199-201). Surface EF-Tu also plays a role in Franciscella tularensis adhesion 
and invasion of monocyte-like cells via interaction with nucleolin (202). Furthermore, 
proteome analysis have demonstrated that EF-Tu is membrane-associated in other 
pathogenic bacteria and could serve as an immunodominant protein (203-205). Thus, 
these observations complement recent reports describing EF-Tu as a novel moonlighting 
protein that exhibit multiple biological functions involved in bacterial benefit or virulence 
(196, 197). 
 The B. burgdorferi genome carries one copy of eftu gene (bb0476) which encodes 
for EF-Tu, a GTP binding protein (206) that is involved essentially in protein synthesis 
(60). Since surface EF-Tu has shown to play roles in virulence in other organisms, we 
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reasoned that EF-Tu localizes on the cell surface to play roles in B. burgdorferi infection 
in mammals. In this pilot study, we demonstrated that EF-Tu was highly immunogenic 
during mammalian infection since it was recognized by antibodies from infected mice 
and Lyme disease patients. However, we found that immunization of mice with 
recombinant EF-Tu (rEF-Tu) in Freund’s adjuvant did not show protection against 
challenge with B. burgdorferi. Our finding demonstrated that EF-Tu resides primarily in 
protoplasmic cylinder inner membrane enriched fractions and associated with outer 
membrane vesicles in small quantities. Nevertheless, our results suggest that 
protoplasmic EF-Tu is an immunoreactive protein that could be examined as a 
serodiagnostic marker during early stages of B. burgdorferi infection.   
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CHAPTER III: MATERIALS AND METHODS 
Bacterial strains and culture conditions 
 B. burgdorferi strain B31-A3 and the isogenic ospCK1 mutant (referred to as 
ospC) and the ospC complemented strains were kindly provided by Dr. P. Rosa and Dr. 
K. Tilly (Rocky Mountain Laboratories, National Institute of Allergy and Infectious 
Diseases, National Institutes of Health) (65). AH130 is an infectious low‐passage strain 
derived from wild-type strain 297 (207). The ospC mutant (referred to as ospC) generated 
in the background of B. burgdorferi strain 297 was previously described (208). Low-
passage, virulent B. burgdorferi strain 5A4NP1 (kindly provided by H. Kawabata and S. 
Norris, University of Texas Health Science Center at Houston) was derived from wild-
type strain B31 by inserting a kanamycin resistance marker in the restriction modification 
gene bbe02 on plasmid lp25.(209). Spirochetes were grown using standard Barbour-
Stoenner-Kelly II (BSK-II) medium containing the relevant antibiotic. Cultures were 
maintained at 37 °C, pH 7.5 °C in a 5% CO2 incubator and were passaged no more than 
three times from the original stocks. To measure growth rate of GFP-expressing 
spirochetes, cells were grown in BSK-II medium at 37 °C, pH 7.5 or pH 6.8. The cell 
density of cultures was monitored by counting spirochetes under the dark-field 
microscope (Olympus America Inc, Center Valley, PA). 
Generation of GFP-expressing B. burgdorferi strains 
 Wild-type B. burgdorferi strain B31-A3 or AH130 and the isogenic ospC mutants 
were transformed with shuttle vector pTM61 (generously provided Dr. G. Chaconas, 
University of Calgary), that harbors a gene encoding GFP under the control of a 
constitutive flaB promoter from B. burgdorferi (50). Electrotransformation of B. 
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burgdorferi strains was performed as previously described (210). Selection for 
transformants was performed from cultures plated in a 96-well tissue culture plates (200 
μl/well) containing liquid BSK-II medium and relevant antibiotic markers (50 μg ml−1 
gentamicin and 200 μg ml−1 kanamycin or 50 μg ml−1 streptomycin). Positive wells 
containing transformants were identified by a color change of the medium, and the 
presence of fluorescent spirochetes was confirmed with an Axio Imager.A2 fluorescence 
microscope (Carl Zeiss, Jena, Germany).  
 The complemented ospC mutant carrying GFP was performed by transforming 
the ospC mutant with pTM61-derived shuttle vector carrying both a GFP gene and a 
wild-type ospC gene (pSEC002, primers to generate this construct listed in Table 2). 
Transformants were visualized by fluorescent microscopy and subjected to 
immunoblotting to verify the restoration of OspC (ospC-gfp/ flgBp-ospC referred as 
ospC-co). 
Recombinant protein 
 The B. burgdorferi gene bb0476 encoding EF-Tu from strain B31 was amplified 
by PCR using the primer pair Sa-bb0476-5 (forward) and Sa-bb0476-3 (reverse) (Table 
2). The resulting amplicon was cloned into pET100/D-TOPO (Invitrogen, Carlsbard, CA) 
to generate plasmid pSCEFTUCT2, which was then entirely sequenced on both strands to 
rule out the possible introduction of undesired mutations during PCR and cloning 
procedures. EF-Tu-6×His fusion protein was expressed in Escherichia coli Rosetta (DE3) 
(Novagen, Madison, WI). Briefly, exponentially grown cells (A600, 0.5) were induced for 
5 h at 37°C with 0.1 mM (final concentration) of isopropyl-β-d-thiogalactopyranoside 
(IPTG). Cells were pelleted and resuspended in a buffer containing 400 mM NaCl, 40 
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mM NaH2PO4 (pH 7.2), 500 mM DTT, and  100 mM protease inhibitor PMSF (Sigma-
Aldrich, St. Louis, MO). Cells were then lysed by brief sonication and debris was cleared 
by centrifugation. The resulting supernatant was loaded onto nickel-charged resin (Ni 
NTA, Qiagen, Valencia, CA) for affinity purification. After washing, protein was eluted 
with 500 mM imidazole and then concentrated with 40% ammonium sulfate. Protein was 
collected by centrifugation, dissolved in buffer solution (50 mM potassium phosphate, 
10% glycerol, 0.1 mM EDTA buffer), and dialyzed against the same buffer overnight at 
4°C. The dialysate was centrifuged at 5,000 × g for 15 min, and the supernatant was 
filtered in 10,000 kDa molecular mass cutoff membranes (Fisher Scientific, Pittsburgh, 
PA) prior to use. Protein purity was assessed by SDS-PAGE. Protein concentration was 
measured using a Bradford protein assay kit (Bio-Rad, Hercules, CA).  
Construction of a shuttle vector for constitutive expression of EF-Tu 
 To constitutively express the wild-type eftu, the DNA fragment of eftu was 
amplified by PCR from B. burgdorferi B31-A3 using primers PRYY7 and PRYY8 with 
restriction enzyme sites NdeI and PstI and a HA epitope tag sequence, respectively.  The 
PCR products were digested with NdeI and PstI and inserted into the pBSV2-derived 
shuttle vector pJD55 under the control of a constitutive Borrelia promoter, PflaB. The 
resulting shuttle vector, pYY003, was verified by sequencing and then transformed into 
B31-A3 as described previously (184). The transformants (B31-A3/PflaB-eftu-HA) were 
selected in a 96-well tissue culture plates (200 μl/well) containing liquid BSK-II medium 
and relevant antibiotic markers (200 μg ml−1 kanamycin). The level of expression of EF-
Tu in B. burgdorferi transformants was also verified by immunoblotting.  
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Protein electrophoresis and immunoblotting  
 SDS-PAGE and immunoblotting were performed as previously described (211). 
Monoclonal antibodies directed against OspC (182-105-D2), OspA (14D2-27), and the 
loading control FlaB (8H3-33) were described previously (212), and a dilution of 1:2000, 
1:1,000, and 1:500 dilutions, respectively were used in our studies. A polyclonal mouse 
antibody against EF-Tu (1:15,000 dilution) was used to detect recombinant EF-Tu and 
EF-Tu in B31 whole-cell lysates using nitrocellulose membranes (Bio-Rad). HA.11 
monoclonal antibody (1:1,000; clone 16B12; Covance, Princeton NJ) was used to detect 
HA-tagged EF-Tu in whole-cell lysates. OspA, FlaB, and/or EF-Tu antibodies were 
detected with horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG secondary 
antibody (1:1,000; Santa Cruz Biotechnology, Santa Cruz, CA). Detection of peroxidase 
activity was determined in membranes using both 4-chloro-1-napthol and H2O2 (Fisher 
Scientific) solution or an enhanced chemiluminescent method (Pierce ECL Western 
Blotting Substrate, Thermo Scientific, Rockford, IL). 
 Sera from four C3H/HeN mice infected with 5A4NP1 (106 spirochetes / mouse) 
were pooled and used to assess the appearance of antibody response against recombinant 
EF-Tu protein. Sera was diluted 1:600 in 1 x PBS - 0.05% Tween-20 (PBS-Tween) and 
incubated at RT for 2 h with nitrocellulose membrane strips containing approximately 
500 ng of recombinant EF-Tu protein per strip.  
 Human sera obtained from the CDC Lyme patient serum panels were used in 
immunoblotting assays to determine antibody reactivity to recombinant EF-Tu (500 
ng/per strip). We used sera from 10 Lyme disease patients that tested positive by ELISA 
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and Western Blot to Lyme disease. Additionally, sera from 3 healthy donors, collected 
from areas of the U.S. where Lyme disease is not endemic, were used as controls in these 
immunoblotting assays. All human sera were diluted 1:100 in PBS-Tween for 
immunoblotting (213), as described above. 
Immunofluorescence assay  
 To determine whether EF-Tu is surface exposed, B31-A3 and B31-A3/PflaB-eftu-
HA spirochetes from mid-logarithmic phase cultures were probed in solution as 
previously described (214, 215). Briefly, unfixed live spirochetes were incubated at room 
temperature for 1 h in blocking solution (2% BSA in 1 x PBS with 5mM MgCL2) 
containing the primary antibodies of interest. A polyclonal antibody against EF-Tu and a 
monoclonal antibody directed against HA.11 were used at a final dilution of 1:40 and 
1:1000, respectively. Monoclonal antibodies directed against OspA and FlaB were used 
at a final dilution of 1:40. After the primary incubation, spirochetes were washed twice 
and gently resuspended in blocking solution, and then 20 µl of cell mixtures were added 
on silylated microscope slides and air dried (CEL Associates, Pearland, TX). Slides were 
then incubated with a 1:1,000 dilution of fluorescein isothiocyanate - conjugated goat anti 
-mouse IgG (Jackson ImmunoResearch Inc, West Grove, PA) for 1 h at 37°C in a dark, 
humid chamber. Slides were gently washed with blocking soltution and then mounted 
with antifade light mounting medium (Molecular Probes, Eugene, OR). As an additional 
control for these unfixed IFA experiments, spirochetes were incubated for 1h with 
BacTrace fluorescein isothiocyanate-conjugated goat anti-B. burgdorferi antibody 
(Kirkegaard and Perry Laboratories, Gaithersburg, MD) at a 1:100 dilution in blocking 
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solution. The presence of fluorescent spirochetes was confirmed with an Axio Imager.A2 
fluorescence microscope (Carl Zeiss). 
 To detect the presence of EF-Tu, FlaB, and OspA in spirochetes, we also used an 
alternate IFA method in which spirochetes were placed onto silylated slides, air dried, 
and fixed and permeabilized by immersion in acetone solution (71, 214). This fixed IFA 
method was also used to detect the presence of fixed spirochetes in smears of fed tick 
larvae (71).  Slides were then incubated at 37°C for 1 h with blocking solution (PBS-
Tween 20 with 5% goat serum) in a humid chamber. Fixed spirochetes were incubated at 
room temperature for 1 h in blocking solution containing the primary antibodies of 
interest and then followed by washes and incubation with a secondary antibody, as 
described for the unfixed IFA method above. 
Proteinase K accessibility assay 
 Proteinase K (PK) accessibility assays were performed as described (216, 217). 
Briefly, B. burgdorferi B31-A3 or B31-A3/PflaB-eftu-HA (1 × 108/ml) were gently 
washed three times in PBS (pH 7.4) and collected by centrifugation at 4,000 × g for 30 
min. Washed spirochetes were then gently resuspended in 2.5 ml of PBS and split into 
five equal 500 μl volume samples. Four samples were treated with proteinase K (25, 50, 
100 or 200 ug of PK) (Sigma-Aldrich) for 1 h at room temperature (RT) while one 
sample was incubated with 1 × PBS as a control. After incubation, samples were treated 
with 10 μl of PMSF (Sigma-Aldrich) to inactivate PK activity. Samples were 
subsequently pelleted by centrifugation at 10,000 × g for 10 min and resuspended in PBS 
for SDS-PAGE and immunoblotting. 
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TX-114 phase partitioning  
 To determine whether EF-Tu has the amphiphilic properties expected of an 
integral membrane protein, B. burgdorferi B31-A3 cells (109 organisms) were harvested 
and phase-partitioned as described previously (218). The resulting protein pellets were 
resuspended in PBS and subjected to SDS-PAGE and immunoblot analysis using the 
polyclonal antibody directed against EF-Tu or the monoclonal antibody against OspA, 
which is a well-characterized amphiphilic lipoprotein.  
Isolation of outer membrane vesicles  
 Isolation of the OMVs of B. burgdorferi was performed as described (219, 220).  
Briefly 5 × 1010 – 1011 B. burgdorferi cells were washed twice in 1 x PBS (pH 7.4) 
containing 0.1% BSA, resuspended and incubated on a rocker at room temperature for 2 
h in ice-cold 25 mM citrate buffer (pH 3.2) containing 0.1% BSA. The resulting outer 
membrane vesicle and protoplasmic cylinder (PC) inner membrane enriched fractions 
were separated and purified on a sucrose density gradient as detailed (219). This PC 
fraction contains a number of axial filaments and periplasmic and inner membrane 
elements (219). The OMVs were monitored for purity by immunoblotting using 
antibodies against OspA and FlaB. 
Cell lines 
 J2-retroviral infected alveolar macrophage cell line (AMJ2-C11) was purchased 
from ATCC, and grown in DMEM complete culture medium, as described previously 
(221). THP-1 human monocytic cell line was kindly provided by Dr. Janice Blum 
(Indiana University School of Medicine) and cultured in RPMI 1640 medium 
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supplemented 10% FBS, 2mM L-glutamine and 1% penicillin/streptomycin solution. 
Cells were passaged every 3-4 days in fresh RPMI medium. THP-1 cells were 
differentiated into macrophage-like cells by culturing with 100 nM of PMA in RPMI 
medium for 3 days as previously described (222).  PMA-treated THP-1 cells were rested 
in fresh RPMI for a further 4 days before they were used for phagocytosis assays. PMA 
treated THP-1 cells were detached from the flask with nonenzymatic cell dissociation 
solution (Sigma-Aldrich). HL60 human promyelocitic cell line was kindly provided Dr. 
Hal Broxmeyer (Indiana University School of Medicine) and differentiated into 
neutrophil-like cells (PMN-HL60) by culturing with 1.25% (vol/vol) DMSO in DMEM 
medium for 6 days as previously described (223). 
Isolation and immortalization of inflammatory peritoneal macrophages  
 Elicited murine macrophages from C57BL/6 mice were collected by peritoneal 
lavage with PBS 4 days after the injection of 4% thioglycollate, as described previously 
(224). Cells were resuspended in DMEM conditioned medium containing 10% FBS, 10 
mM HEPES, 10 ng M-CSF, and 1% penicillin/streptomycin/amphotericin B solution 
(HyClone; Thermo Scientific) and incubated in a 6-well plate (Costar, Corning, NY) for 
12 h at 37°C with a 5% CO2. Nonadherent cells were removed by washing the 
monolayers with warm serum-free medium. Adherent peritoneal macrophage monolayers 
were infected with the supernatants of J2 cell line producing oncogenic retrovirus and 
mixed with DMEM conditioned medium and 1 µg/ml polybrene (Santa Cruz 
Biotechnology). After 24 h, cells were infected with a second treatment of J2 virus under 
the same conditions to improve transfection efficiency. Immortalized peritoneal 
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macrophages (PMs) were obtained about 4 weeks later  and isolated using a previously 
described method (221).  
Mouse strains and inoculation with B. burgdorferi strains.  
 NOD-scid IL2rγnull mice (designated NODSCIDg) were acquired from either 
Jackson Laboratories (Bar Harbor, ME) or the In vivo Therapeutics Core at the Indiana 
University Simon Cancer Center (Indianapolis, IN).  C57BL/6 (B6) bTie2-Cre mice were 
acquired from Jackson Laboratories, and B6 eTie2-Cre and B6 Stat3 floxed mice 
(Stat3F/F) were a gift from Dr. Xin Yuan Fu (Indiana University School of Medicine). 
Mice with conditional deletion of Stat3 in endothelial cells (Stat3E-/-) or myeloid cells 
(Stat3B-/-) were generated by mating Stat3F/F with either eTie2-Cre or bTie2-Cre as 
previously described (225, 226). Of note, Stat3B-/- do not survive beyond 6 weeks of age, 
whereas Stat3E-/- and Stat3F/F are viable and develop normally (225, 226). C.B-17 scid and 
C3H/HeN mice were acquired from either Harlan Laboratories (Indianapolis, IN) or 
Taconic Laboratories (Germantown, NY).  Some C.B-17 scid mice (hereafter designated 
SCID) were also from a breeding colony maintained at the Laboratory Animal Research 
Center (LARC) in Indiana University School of Medicine. Plac8-/- mice were acquired 
from Jackson Laboratories. Mice were housed under specific pathogen-free conditions at 
LARC. All mouse strains used in these studies are listed in Table 3.  
 For mouse infection, groups of 4- to 6-week-old C3H/HeN, SCID, and 
NODSCIDg were inoculated intradermally (i.d.) at the base of the tail, intraperitoneally 
(i.p.) or intravenously (i.v.) with a dose of either 103 or 105 spirochetes per mouse as 
indicated in each experiment. Groups of 4 week-old B6 Stat3B-/- and Stat3F/F mice and 8 
week old B6 Stat3E-/- and Stat3F/F mice were i.d. inoculated with 105 or 106 spirochetes 
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per mouse as indicated in the appendix section. Mice were euthanized at specified time 
points ranging from 2 days to 6 weeks post-inoculation. All experiments were performed 
with the approval of the Indiana University Institutional Animal Care and Use 
Committee. 
 Infectivity was assessed weekly by culturing ear-punch biopsies in BSK-II 
medium supplemented with relevant antibiotic markers used to select each strain as well 
as the Borrelia antibiotic cocktail (50 μg ml−1 rifampicin, 20 μg ml−1 phosphomycin and 
2.5 μg ml−1 amphotericin B). Cultures were evaluated for the presence of spirochetes by 
dark-field microscopy for up to 4 weeks before being designated as negative. A single 
growth-positive culture occurred within 1–3 weeks post-harvest and was used as the 
criterion to determine positive mouse infection in OspC or Stat3 studies. 
Active immunization and infection studies 
 Groups of C3H/HeN mice were immunized with 50 μg recombinant EF-Tu in 
PBS (1:1) with adjuvant (complete Freund's adjuvant; Sigma-Aldrich). Mice received 2 
boosts of 50 μg recombinant EF-Tu in PBS (1:1) with incomplete Freund's adjuvant 
(Sigma-Aldrich) at 14-day intervals. One week after the final boost, mice were inoculated 
with B. burgdorferi strain 5A4NP1 with a dose of 104 spirochetes per mouse. Mice were 
euthanized at either two weeks or five weeks post-inoculation. Infectivity was assessed 
by culturing ear pinna, joints, and heart tissues in BSK-II medium supplemented with the 
relevant antibiotic marker (kanamycin or 50 μg ml−1) as well as the Borrelia antibiotic 
cocktail. A single growth-positive culture occurred within 1 week post-harvest and was 
used as the criterion to determine positive mouse infection. 
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 For tick studies, pathogen-free Ixodes scapularis larvae were obtained from the 
Tick-Rearing Center at Oklahoma State University (Stillwater, OK). The tick-mouse 
experiments were conducted in the Vector-borne Diseases Laboratory at Indiana 
University School of Medicine. At three weeks post-inoculation, unfed larvae were 
placed on immunized mice (~ 50 larvae per mouse). At 72-96 h, these larvae had fully 
engorged and naturally dropped off the mice. A subset of fed larvae were subjected to 
IFA and qPCR analysis to determine B. burgdorferi acquisition and loads. The remaining 
fed larvae were maintained in a humidified chamber and allowed to molt to the nymphal 
stage (about 5 weeks). Two months after molting, unfed nymphs were then allowed to 
feed on immunized mice (~3 nymphs per mouse) and collected within 48 h after 
repletion. Two weeks after tick feeding, mouse tissues were collected and tested for 
infection by culture as described above. 
Fluorometric phagocytosis assay 
 Murine PMs and PMA-treated THP-1 cells were seeded at a density of 3 × 105 
cells/well in replicates of 5 in 96-well tissue culture plates with opaque sides and 
optically clear bottoms (Costar). On the following day, a subset of wells were 
preincubated for 30 min with the phagocytosis inhibitor cytochalasin D (5 µg/ml; EMD 
Chemicals, Gibbstown, NJ) before phagocytosis assays. PMs or PMA-treated THP-1 
cells were challenged with GFP-expressing spirochetes at a multiplicity of infection 
(MOI) of 100:1 and co-incubated at 37°C with 5% CO2 for 2 h. In scavenger receptor 
blocking experiments, a subset of wells were pretreated for 30 min with cytochalasin D 
(5 µg/ml) as a control of noninternalized spirochetes or 2.4G2 hybridoma supernatants 
containing antibodies that specifically block mouse Fcγ receptor (227). Then the 
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experimental samples were preincubated with scavenger receptor blockers for 30 min 
before phagocytosis assay. Selected compounds for scavenger receptor experiments 
included fucoidan (100-500 µg/ml; Sigma-Aldrich); poly I or the negative control 
compound poly C (400 µg/ml; Sigma-Aldrich); monoclonal anti-mouse MARCO (12 
µg/ml, clone ED31, AbD Serotec, Raleigh, NC) or anti-mouse IgG1 (12 µg/ml, clone R3-
34, BD Pharmingen, San Diego, CA); monoclonal anti-mouse CD36 (50 µg/ml, clone 
ME542, Santa Cruz Biotechnology) or anti-mouse IgA (50 µg/ml, clone M18-254, BD 
Pharmingen) for phagocytosis assays. PMs were then challenged with GFP-expressing 
spirochetes at MOI of 100 and incubated at 37°C with 5% CO2 for 2 h. After infection, 
cells were washed 3 times with PBS before adding 0.2% of trypan blue (Sigma-Aldrich) 
to quench fluorescence of extracellular bacteria. Fluorescence was determined using a 
microplate fluorometer, SPECTRAMax GEMINI EM at settings of 485 excitation/535 
emission (Molecular Devices, Sunnyvale, CA). The phagocytic index (PI) represents the 
fluorescence of intracellular spirochetes phagocytosed by macrophages and is expressed 
in relative fluorescence units (RFUi) as previously described (228). The PI was 
calculated by subtracting the fluorescence of extracellular spirochetes from cytochalasin 
D treated wells from the total fluorescence of the experimental samples. 
Flow cytometry and microscopy 
 GFP-expressing spirochetes were harvested for phagocytosis assay as described 
above. Murine PMs, PMA-treated THP-1 cells or PMN-HL60 cells were challenged with 
GFP-expressing spirochetes at an MOI of 100:1 for 2 h. Unstained cells (without GFP-
expressing spirochetes) were used as negative controls. Cells were washed twice in 
FACS buffer (1x PBS, 2 mM EDTA and 0.5% FCS) and then fixed in FACS buffer 
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containing 1% paraformaldehyde. Samples were analyzed using a FACSCalibur flow 
cytometer (BD Biosciences, San Jose, CA). To estimate the percentage of GFP-positive 
macrophages, cells were gated by forward and side scatter properties, and GFP-positive 
cells were identified in the FL1 channel. Cell debris interpreted as dead cells were 
excluded from analysis. Data were analyzed with Cellquest (BD Biosciences) software 
and histograms were edited in FlowJo software (Tree Star, Ashland, OR). 
 For immunofluorescence microscopy using murine PMs, cells were seeded at a 
density of 3 × 105 cells/well in triplicates in 12-well tissue culture plates (Costar). PMs 
were challenged with GFP-expressing spirochetes at an MOI of 100:1 and co-incubated 
at 37°C with 5% CO2 for 2 h. Samples were then washed three times with 1 x PBS and 
incubated with 0.2% trypan blue before microscopy analysis. Fluorescent signal 
corresponding to GFP positive cells was then imaged using an EVOS fl digital 
fluorescence microscope (Advanced Microscopy Group, Bothell, WA) using GFP filter 
(magnification, x10). As a control for these experiments, a subset of infected cells were 
not quenched with trypan blue and another subset cells were treated with cytochalasin D 
(5 µg/ml) to assess background fluorescence. Image J software was used for image 
analysis and quantifications of the number of GFP positive cells.  
In vivo phagocyte depletions  
 Clodronate encapsulated in liposomes (clodronate liposomes) were purchased 
from www.clodronateliposomes.com (Vrije University, Amsterdam, The Netherlands). 
To deplete F4/80+ phagocytes in the skin, 50 µl of clodronate liposomes or PBS-
containing liposomes (PBS liposomes, control) were i.d. injected into SCID mice 48 and 
24 h before challenge with B. burgdorferi strains at the same treatment site. SCID mice 
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were then i.d. and i.p. (150 µl) injected with either clodronate- or PBS- liposomes after 
24 h post-challenge. In order to reduce recruitment of monocytes to the skin, SCID mice 
were i.p. injected with either clodronate- or PBS- liposomes 48 h or 96 h post-challenge 
(229).  
 For neutrophil depletion studies, we used the anti-Ly6G antibody method (clone 
1A8, Bio-X-Cell, West Lebanon, NH) that effectively induces neutropenia in mice (230, 
231). Briefly, groups of SCID and C3H/HeN mice were treated with intraperitoneal 
injections of 250 µg/dose of anti-Ly6G 24 h and 2 h before ospC challenge and 24 h post-
challenge. As a comparison control group, SCID and C3H/HeN mice were injected with 
three doses of 250 μg/dose of isotype antibody rat IgG2a (clone R35-95, BD Biosciences) 
or control rat IgG (Sigma-Aldrich).  
Quantitative PCR and real-time RT-PCR  
 For quantification of B. burgdorferi DNA in mice and ticks, total DNA was 
isolated from joint tissue and fed larvae (9-18 ticks per group) using DNeasy blood & 
tissue kit as described in the manufacturer's protocols (Qiagen). qPCR of genomic DNA 
was performed using the RT2 SYBR Green ROX qPCR Mastermix (Qiagen). The 
oligonucleotide primer pairs used to detect flaB, mouse nidogen (a gene coding for a 150 
kDa glycoprotein), mouse β-actin, and tick actin were flaB-XF F/R, nidogen F/R, 
qhxMactin F3/R3, and qTactin-F/R, respectively (Table 2) (210, 232, 233). Reactions 
were carried out on an ABI Prism 7000 real-time PCR machine (Applied Biosystems, 
Pleasanton, CA). Calculations of DNA copy number of flaB were normalized with the 
copy numbers of either the mouse nidogen or actin genes or the tick actin gene, as 
indicated in Results. 
 53 
 
 For real-time RT-PCR experiments, total RNA from murine peritoneal 
macrophages was extracted using TRIzol reagent (Invitrogen) according to the 
manufacturer's instructions. Complementary DNA was synthesized using a reverse 
transcription system (iScript, Bio-rad), and RT-PCR was performed with primers for tnfa, 
il1b, il10, and β-actin (Table 2) on the CFX96 Real-Time PCR Detection System (Bio-
Rad Laboratories) as previously described (234). Expression levels of transcripts studied 
were normalized to the β-actin level, and the relative changes in gene expression were 
calculated using the comparative threshold cycle (Ct) and calculated relative to control 
uninfected cells (ΔΔCt method). 
 The genotype of the offspring from crossing Stat3F/F × eTie2-Cre or Stat3F/F × 
bTie2-Cre was determined by conventional PCR as previously described (225). To 
determine the genotype of mice deficient in Stat3 in endothelial cells, we used CreF/CreB 
primers specific for Cre recombinase that yield a PCR product of 300 bp and I-17F/E-
17B primers that yield a PCR product of 490 bp for the Stat3 wild-type allele and 520 bp 
for the floxed allele. To determine the genotype of mice deficient in Stat3 in myeloid 
cells, we used CreF/CreB primers for Cre recombinase and 12867-F/13071-R or 
oIMR9042-R primers that yield a PCR products of 361 bp for the Stat3 wild-type allele 
and 377 bp for the floxed allele (Table 2).  
Leukocyte counts, Histology and Immunohistochemistry (IHC) 
 Peripheral blood from mice was collected by cardiac puncture after carbon 
dioxide narcosis. Leukocyte numbers were immediately determined using the hematology 
analyzer Hemavet 950FS (Drew Scientific, Oxford, CT). 
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 For histology, skin sections (site of inoculation) were collected with 8-mm punch 
biopsy (Acuderm, Fort Lauderdale, FL) and fixed in 4% paraformaldehyde. Rear limbs 
were fixed in 10% neutral buffered formalin and decalcified with 10% EDTA solution. 
Tissues were embedded in paraffin, sectioned at 5 µm, and stained with H&E. Sections 
were viewed on a Leica DM3000 microscope (Leica Microsystems Inc., Buffalo Grove, 
IL). 
 Immunohistochemical staining for F4/80+ cells was performed at the IHC core 
facility at Indiana University School of Medicine. Briefly, antigen retrieval was carried 
out in Dako PT module using low pH retrieval buffer (Dako, Carpintenia, CA). Sections 
were incubated with rat anti-mouse F4/80 antibody at a 1:100 dilution (AbD Serotec), 
and subsequently incubated with biotinylated donkey anti-rat antibody at 1:100 dilution 
(Jackson ImmunoResearch, West Grove, PA). Detection was accomplished using the 
LSAB2 method (Dako). Of note, the F4/80 monoclonal antibody has been widely used to 
detect mature tissue macrophages in mice (235, 236). Thus, murine macrophages from a 
spleen section were used as positive control.  
 To perform quantitative analysis of F4/80+ stained sections, slides were scanned 
with an Aperio whole-slide digital imaging system (ScanScope CS, Aperio Technologies, 
Inc., Vista, CA). Skin sections were analyzed using the ImageScope Positive Pixel Count 
algorithm. The default parameters of the Positive Pixel Count (hue of 0.1 and width of 
0.5) were used to detect F4/80+ cells in sections. Data were collected by counting the 
number of strong positive staining per high power field, then averaging the results of 3 
randomly selected regions (fixed region size = width of 300 pixels and height 300 pixels) 
per skin section.  
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 Similar skin sections (site of inoculation) were evaluated by Warthin-Starry stain 
and indirect IHC for the presence of B. burgdorferi using a previously described methods 
(237, 238). Sections were incubated for 12 h at 4 °C with 1:1000 dilution of a polyclonal 
immune serum from B. burgdorferi-immunized rabbits (generously provided by Stephen 
Barthold, University of California-Davis).  
Statistics 
 Data are presented as the mean ± SEM and were analyzed with the Prism 5.0 
statistical program (GraphPad Software, San Diego, CA). Comparisons among groups 
were performed with one-way ANOVA followed with post hoc test as indicated in figure 
legends. Comparisons among two experimental groups were analyzed by Student’s t-test. 
A p value ≤ 0.05 was considered significant. 
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Table 2. Primers used in these studies.  
Primer  Sequence (5’ → 3’) 
ospC B31-3 F GGAGGTTTCCATGAAAAAGAATACATTAAGTGCA 
ospC B31-3 R ATGCTGCAGTTAAGGTTTTTTTGGACTTTCTGC 
flgBp F TGAGGTACCATGTTTAAGGTTT 
flgBp R TTCTTTTTCATGGAAACCTCCCTCAT 
pSEC002-F1 GAGACCACATGGTCCTTCTTGAG  
pSEC002-R1 GCGATTAAGTTGGGTAACGCC  
Sa-bb0476-5  CACCATGAAATTTAGGAGGTTAGTCATGGC 
Sa-bb0476-3 CTATTCCAATATCTCAAGAATTCTTCCTG 
PRYY7 GCAGCCATATGGCAAAAGAAGTTTTTCAA 
PRYY8 
CGTCTGCAGTTAAGCGTAATCTGGAACATCGTATGGGTATTCC
AATATCTCAAGAATTCTTCCT 
qTactin-F CGGGACCTGACCGACTACCTGATG  
qTactin-R CTCCTTGATGTCGCGGACAATTTC  
qhxMactin-F3 AGAGGGAAATCGTGCGTGAC 
qhxMactin-R3 CAATAGTGATGACCTGGCCGT 
flaB-XF F GCTCCTTCCTGTTGAACACCC 
flaB-XF R CTTTTCTCTGGTGAGGGAGCTC 
nidogen F CCAGCCACAGAATCACATCC 
nidogen R GGACATACTCTGCTGCCATC 
tnfa-F ACTTGGTGGTTTGCTACGA 
tnfa-R GATGAGAAGTTCCCAAATGGC 
il1b-F CTCTTGTTGATGTGCTGCTG 
il1b-R GACCTGTTCTTTGAAGTTGACG 
il10-F ATGGCCTTGTAGACACCTTG 
il10-R GTCATCGATTTCTCCCCTGTG 
mouse-BAC-F CTGCCTGACGGCCAAGTC 
mouse-BAC-R CAAGAAGGAAGGCTGGAAAAGAG 
CreF CGATGCAACGAGTGATGAGG 
CreB CGCATAACCAGTGAAACAGC 
I-17F ATTGGAACCTGGGACCAAGTGG 
E-17B ACATGTACTTACAGGGTGTGTGC 
12867-F  AGTTCTCGTCCACCACCAAG 
13071-R  CCTTGTGTGGTCTGAGAACGT 
oIMR9042-R CTTCGTATAGCATACATTATA 
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Table 3. Mouse strains used in these studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mouse strain 
 
Immune system phenotype 
C3H/HeN Normal immune system 
NOD-scid IL2rγnull  Lacks mature B and T cells, functional NK cells and C5 
complement 
C.B-17 scid Lacks mature B and T cells 
C57BL/6 bTie2-Cre Myeloid-specific Tie2 gene promoter drives the expression of 
Cre  
C57BL/6  eTie2-Cre Endothelial-specific Tie2 gene promoter drives the 
expression of Cre 
C57BL/6 Stat3 floxed The stat3 gene is flanked by loxP sites 
C57BL/6 Stat3B-/- Deletion of stat3 gene from myeloid cells 
C57BL/6 Stat3E-/- Deletion of stat3 gene from endothelial cells 
C57BL/6 Plac8-/- Targeted mutation of plac8 gene from epithelial cells, 
macrophages, and granulocytes 
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CHAPTER IV: RESULTS 
Part I- Outer Surface Protein OspC protects Borrelia burgdorferi from phagocytosis 
by macrophages 
The ospC mutant cannot establish infection in NODSCIDg mice deficient in lytic 
complement and NK, B and T cells  
 Previous studies have shown that the ospC mutant cannot establish infection in 
C3H/HeN and SCID mice that lack functional T and B cells (49, 64, 65, 177), suggesting 
that innate immunity is involved in clearance of ospC mutant spirochetes in mice. To 
investigate which innate factors are involved in clearance of the ospC mutant in vivo, we 
examined the infectivity of the ospC mutant in another mouse strain, NODSCIDg, which 
are deficient in T and B cells, as well as lacking C5 complement and functional NK cells 
(239). Loss of complement-factor C5 prevents the activation of C5b and thereby 
inhibiting the formation of the C5b-9 membrane attack complex (239, 240). Groups of 
NODSCIDg mice were i.d. injected with either wild-type B31-A3 or the ospC mutant. 
We used an inoculum of 103 spirochetes per mouse, as previously reported (49, 64, 65, 
99). NODSCIDg mice were also inoculated intravenously, to assess whether the injection 
site plays a role in the infectivity of the ospC mutant. As controls, groups of SCID and 
C3H/HeN mice were also challenged with wild-type or the ospC mutant. Whereas wild-
type B31-A3 spirochetes were readily detectable in all tested tissues from NODSCIDg, 
SCID and C3H/HeN mice after 3 weeks post-challenge, no ospC mutant spirochetes were 
detected in tissues from mice inoculated with 103 spirochetes per mouse (Table 4). This 
result is similar to previous studies with immunocompetent and SCID mice (49, 65, 177). 
The ospC mutant was not infectious in NODSCIDg mice even after 6 weeks post-
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inoculation (data not shown), regardless of the route of inoculation. These results suggest 
that, in addition to lymphocytes, innate components such as lytic complement and NK 
cells are not the major factors that eliminate the ospC mutant in vivo.   
Table 4. Infectivity of wild-type B. burgdorferi (B31-A3) and the isogenic ospC 
mutant in NODSCIDg, SCID, and C3H/HeN mice.  
* Spirochetes were inoculated either intradermally (i.d.) or intravenously (i.v.) in BSK as 
vehicle. 
^ All mice were euthanized at 3 weeks post-inoculation (PI). Isolation of spirochetes was 
attempted from skin-site of inoculation, ear pinna, tibio-tarsal joint, heart base and spleen.  
Culture results expressed as number of mice infected/number of mice tested. Infectivity 
experiments were conducted 3 separate times. 
 
Establishment of dose and vehicle for inoculation to study the ospC mutant in vivo 
 Since NODSCIDg have defective functions in different innate cells, we chose an 
immunodeficient model with an intact innate immune system such as SCID mice to 
assess the role of innate cells in clearance of the ospC mutant. To establish a system to 
study the ospC mutant in SCID mice, the infectious dose and the vehicle to deliver 
spirochetes were evaluated in a series of infectivity experiments. Spirochetes used in the 
infectivity studies above were inoculated in mice using BSK-II growth medium, which is 
a commonly used vehicle to test infectivity of B. burgdorferi strains and mutants in mice. 
 
 
Route of 
Inoculation* 
Dose B. burgdorferi 
strain 
3 weeks 
PI^ 
NODSCIDg i.d. 103 B31-A3 3/3 
NODSCIDg i.d. 103 ospC 0/3 
NODSCIDg i.v. 103 B31-A3 3/3 
NODSCIDg i.v. 103 ospC 0/3 
SCID i.d. 103 B31-A3 3/3 
SCID i.d. 103 ospC 0/6 
C3H/HeN i.d. 103 B31-A3 3/3 
C3H/HeN i.d. 103 ospC 0/6 
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Since BSK-II is a complex medium with 6% rabbit serum and 5% BSA (241) that may 
alter the host immune response at the skin-site of spirochetal inoculation, we next tested 
whether the ospC mutant can establish infection using a minimal medium vehicle such as 
PBS buffer. We also compared two routes of inoculations, intradermal or intraperitoneal.  
  Groups of SCID mice were injected with an inoculum of 105 of either B31-A3 or 
ospC mutant spirochetes per mouse. We increased the inoculum size to 105 spirochetes 
since PBS or saline could affect viability of spirochetes based on our preliminary 
infectivity experiments (data not shown). Similar to infectivity experiments above, the 
ospC mutant was not detected by culture in any harvested tissues from SCID mice when 
injecting 105 spirochetes per mouse, regardless of vehicles used (PBS buffer or BSK-II 
medium) or route of inoculation (i.d. or i.p.) (Table 5). Thus, the infectivity results using 
105 spirochetes with PBS as a vehicle provide a well-defined minimum medium with 
which to explore the interaction of OspC-lacking spirochetes with innate host factors in 
vivo. 
Table 5. Infectivity of wild-type B. burgdorferi (B31-A3) and the ospC mutant in 
SCID mice using different vehicles and routes of inoculation.  
Bb strain  Dose  Route of 
Inoculation*
Vehicle 3 weeks 
PI^ 
B31-A3  105  i.d. PBS 3/3 
 105  i.p. PBS 3/3 
 105  i.d. BSK 3/3 
ospC 105  i.d. PBS 0/3 
 105  i.p. PBS 0/3 
 105  i.d. BSK 0/3 
* Spirochetes were inoculated either intradermally (i.d.) or intraperitoneally (i.p.) in 
either PBS or BSK as vehicles. 
^ All mice were euthanized at 3 weeks PI. Isolation of spirochetes was attempted from 
skin-site of inoculation, ear pinna, tibio-tarsal joint, heart base and spleen.  Culture results 
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expressed as number of mice infected/number of mice tested. Infectivity experiments 
were conducted in 2 separate trials. 
 
Phagocytes contribute to the clearance of the ospC mutant at the skin inoculation 
site  
 The data above, along with previous studies by others, suggest that B cell, T cell, 
lytic complement and NK cells were not the major host factors that eliminate the ospC 
mutant in vivo. We next investigated whether professional phagocytes may play an 
important role in the clearance of the ospC mutant. For this purpose, we chose SCID 
mice since they have a functional innate immune system (240, 242). Groups of SCID 
mice were treated with clodronate liposome to induce depletion of phagocytes in the 
skin-site of inoculation of B. burgdorferi strains. Immunostaining of skin sections 
harvested 7 days post-challenge confirmed a significant reduction in F4/80 positive 
phagocytes in SCID mice treated with clodronate and challenged with either wild-type or 
ospC-deficient spirochetes (Figure 6). These immunostaining results are in agreement 
with previous studies showing that subcutaneous injections of clodronate liposomes 
selectively depleted the number of resident macrophages in mouse models of skin 
disorders (229, 236).  
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Figure 6. Clodronate liposome administration reduced the number of F4/80+ 
phagocytes at the site of inoculation. A) Representative images of 
immunohistochemical staining for detection of F4/80+ cells (brown) in skin sections 
(magnification, ×40) from SCID mice treated with either clodronate or PBS liposomes 
(LPBS) 7 days after infection. B) Quantification of F4/80+ cell of the images in (A) using 
Aperio image analysis algorithms (y-axis represents the number of positive staining 
within the analyzed region / 103). Data represent the mean ± SEM for three separate fixed 
regions per mouse skin section (n = 3 mouse skin section per group). Student’s t test was 
used to determine significance (*, P < 0.05).  
 
 To determine the effect of phagocyte depletion on the infectivity of the ospC 
mutant, we examined the presence of spirochetes in various tissues 7 days post-challenge. 
As shown in Figure 7, the ospC mutant spirochetes were able to establish infection in the 
majority of mice (90%; 9/10) treated with clodronate. The ospC mutant was re-isolated 
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from skin-site of inoculation, heart blood and/or joints. Furthermore, ospC spirochetes 
were detected by special staining of spirochetes at the skin-site of inoculation in 
clodronate-treated SCID mice even at day 7 post-challenge (Figure 7). As expected, the 
ospC mutant could not infect the SCID mice treated with PBS liposomes (Figure 7A-B).  
In clodronate-treated mice, the ospC mutant disseminates to tissues distant from the 
inoculation site, and the dissemination correlated with high neutrophil counts in blood 
similar to what is observed in SCID mice infected with wild-type spirochetes (Figure 7A 
& 8). Collectively, these results show that phagocytes contribute to the clearance of the 
ospC mutant at the skin inoculation site in SCID mice.  
 Spirochetal burden in joint tissues was quantified by real-time qPCR analyses at 
day 7 post-infection. When infected with wild-type spirochetes, clodronate-treated mice 
developed the highest spirochetal burden in joints (Figure 7C). When infected with the 
ospC mutant, joints from PBS liposome-treated SCID mice did not have detectable B. 
burgdorferi DNA (Figure 7C), which was consistent with the culture-negative results 
from tissues, including joints from this group of animals (Figure 7C). This result 
provides evidence that the ospC mutant was not able to colonize the joint in PBS 
liposome-treated mice, whereas the wild-type strain was readily detectable in joints at 7 
days post-infection in PBS liposome-treated animals. Although the ospC mutant 
spirochetes were readily detectable in joints of clodronate-treated animals, the bacterial 
load was at least ten-fold lower than the bacterial load in joints from clodronate-treated 
mice that were infected with wild-type spirochetes (Figure 7C). These data suggest that 
phagocytes contribute to the clearance the ospC mutant in SCID mice, but removal of 
these cells in SCID mice is not sufficient to restore ospC spirochetal burden in joints to 
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wild-type levels.  
 
Figure 7. The ospC mutant disseminates and colonizes F4/80+ phagocyte-depleted 
SCID mice. A) Infectivity of wild-type, the ospC mutant, or the complemented mutant 
strain (ospC- comp) in mice either treated with clodronate or PBS liposomes (control). 
The number of mice used in each group for wild-type, ospC mutant, and the 
complemented strains was 9, 10, and 7, respectively. Infectivity for each bacterial strain 
was determined from cultivation of spirochetes from the skin-site of inoculation, heart 
blood, tibio-tarsal, and ear pinna at day 7 post-challenge. B) A representative Warthin-
Starry stain that demonstrated the presence of  ospC mutant spirochetes at the skin site of 
inoculation (right bottom inset, magnification, x40) from clodronate liposome-treated 
SCID mice (culture positive, N = 5). Spirochetes were observed in dermis (black arrows) 
and fasciae underneath skeletal muscle. No ospC mutant spirochetes were detected at the 
skin site of inoculation (left bottom inset) of PBS liposome-treated SCID mice at day 7 
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post-challenge (culture negative, N = 5).  C) Quantitation of spirochetal burden in tibio-
tarsal joints of clodronate-treated mice. The isolated DNA was subjected to qPCR 
analyses for B. burgdorferi flaB gene and mouse nidogen housekeeping gene. Data are 
representative of two separate experiments, and each black line indicates the mean ± 
SEM for nine to ten mice in each group. Comparisons of PBS- and clodronate-treated 
animals were performed using unpaired Student’s t test with Welch’s correction (*, P ≤ 
0.05, ***, P ≤ 0.0005, NS = not significant). 
 
 To determine whether systemic dissemination B. burgdorferi had an effect on 
leukocytes, we compared leukocyte numbers from peripheral blood collected at day 7 
post-challenge from PBS- and clodronate- liposome treated animals. Neutrophils were 
significantly elevated in PBS- or clodronate-liposome treated groups of mice with 
disseminated B. burgdorferi infection. Conversely, neutrophils were normal in uninfected 
SCID mice that were treated with PBS- liposomes and challenged with ospC spirochetes 
(Figure 8), as this group of mice had cleared the ospC mutant from the skin-site of 
inoculation. The leukocytes in blood from this group of animals were at normal levels 
comparable to naïve mice (Figure 8). Together, these findings suggest that spirochetal 
dissemination triggered the recruitment of neutrophils in SCID mice, regardless of 
clodronate treatment. 
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Figure 8. Neutrophils are increased in the circulation when B. burgdorferi strains 
have established infection in SCID mice treated with clodronate or PBS liposomes. 
Peripheral blood was collected at day 7 post-challenge in EDTA-coated tubes and was 
analyzed with a HEMAVET 950 multispecies hematology cell counter. Normal reference 
values of total white blood cells and neutrophils in mice are ≤ 10.7 and ≤ 2.5 (x 103/μl), 
respectively. Data are representative of two separate experiments and each bar represents 
mean ± SEM for seven to ten mice per treatment group. Total white blood cell and 
neutrophil counts from 3 naïve age-matched SCID mice are shown as a comparison 
group (brown bars). Comparisons of experimental treated-groups were performed with 
one-way ANOVA followed by Bonferroni’s post hoc test (*, P < 0.05; ^, P < 0.01; &, P 
< 0.001).  
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Treatment of mice with neutrophil-depleting antibody does not restore infectivity of 
the ospC mutant  
 Since neutrophils are commonly recruited to the sites of spirochetal infection in 
mice (143, 181), we then assessed whether removal of neutrophils in mice would allow 
the ospC mutant to survive and disseminate in vivo. To test this, groups of SCID and 
C3H/Hen mice were treated with anti-Ly6G monoclonal antibody that specifically 
depletes neutrophils in mice (230). We found that the ospC mutant was not able to 
survive at the skin-site of inoculation and disseminate to tissues in anti-Ly6G treated 
SCID mice 48 h and 7 days post-challenge (Table 6). Furthermore, the ospC mutant 
could not establish infection in anti-Ly6G-treated C3H/HeN mice that exhibited a 
profound neutropenia (85% depletion, Figure 9) during the first 48 h post-challenge. 
Together, these results indicate that removal of neutrophils during early events of 
spirochetal infection is not sufficient to restore the ospC mutant infectious phenotype. 
Table 6. The ospC mutant cannot establish infection in SCID and C3H mice treated 
with anti-Ly6G monoclonal antibody.  
 
^ All mice were euthanized at either 48 h or 1 week PI. Isolation of spirochetes was 
attempted from skin-site of inoculation, ear pinna, tibio-tarsal joint, and heart blood. 
Culture results expressed as number of tissues infected/number of tissues tested from 
mice after 48 h and 1 week post-inoculation with ospC spirochetes. 
+ Not determined (ND). 
 
 
 
 
Mouse strain Treatment Dose Bb 
strain 
48 hr 
PI^ 
1 week 
PI^ 
SCID Anti-Ly6G 105 ospC 0/3 0/3 
SCID Control IgG 105 ospC 0/3 0/3 
C3H/HeN Anti-Ly6G 105 ospC 0/3 ND+ 
C3H/HeN Control IgG 105 ospC 0/3 ND 
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Figure 9. Treatment with anti-Ly6G reduces neutrophils in circulation of SCID and 
C3H/HeN mice after 48 h post-challenge with the ospC mutant.  A) Peripheral blood 
from mice treated with either anti-Ly6G antibody or isotype (Iso) control was analyzed 
with a HEMAVET 950 multispecies hematology cell counter within 24 h after the last 
antibody treatment. Data represent the mean ± SEM for three mice per treatment group. 
Comparisons of anti-Ly6G- and isotype-treated groups were performed using unpaired 
Student’s t test with Welch’s correction (**, P ≤ 0.001, * P < 0.01). 
 
Abrogation of OspC increases phagocytosis by macrophages 
 The above observation that phagocytes contributed to the clearance of the ospC 
mutant in vivo prompted us to assess the interaction of these cells with spirochetes. To 
assess this interaction, we first generated GFP-expressing wild-type, ospC mutant, ospC 
complemented spirochetes. Our immunoblotting results showed that both GFP-
expressing wild-type and complemented strains (B31 and 297) were not defective in 
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OspC expression when cells were harvested for these experiments (Figure 10A-B). In 
addition in vitro growth analysis showed that the GFP-expressing ospC mutant 
spirochetes exhibited a similar growth pattern as the GFP-expressing wild-type (B31) 
spirochetes when cultivated under conditions analogous to those present in the 
mammalian host (e.g. 37°C, pH 7.5) and  feeding ticks (e.g. 37°C, pH 6.8) (Figure 11A-
B).  
 
Figure 10. Generation of wild-type, ospC mutant and complemented mutant strains 
expressing GFP. A) Immunoblot showing the OspC production in GFP-expressing 
strains of B. burgdorferi. Top: Coomassie blue-stained gel.  Bottom: Immunoblot probed 
with antibodies recognizing FlaB (control) and OspC. B) Immunofluorescence 
micrograph showing GFP-expressing wild-type (B31-A3, top panel) and the ospC mutant 
(bottom panel) B. burgdorferi strains (Scale bar: 10 µm.) 
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Figure 11. The GFP-expressing ospC mutant exhibited a growth pattern similar to 
that exhibited by the B31 wild-type strain when cultivated in standard BSK-II 
medium. A-B) Growth curves were measured while cells were growing in BSK-II 
medium at 37°C and pH 7.5 or pH 6.8. The initial cell density was 3 × 105 spirochetes/ml 
for each strain. Spirochetes were enumerated daily under dark-field microscopy. Data 
presented here is from one experiment with two independent cultures (S1 = sample 1 and 
S2 = sample 2). Each data point is expressed as the mean from six independent fields. 
 
 Given that phagocytosis is an innate mechanism that phagocytes employ to 
eliminate spirochetes (118), we then investigated the uptake of these GFP-expressing B. 
burgdorferi strains by phagocytes using a fluorometric-based method. We selected 
macrophages for these experiments because these cells are highly phagocytic and express 
the F4/80 marker at high levels on the cell surface. To evaluate the internalization of 
spirochetes in our fluorometric-based phagocytosis assays, murine or human 
macrophages were preincubated for 30 min with 5 μg/ml cytochalasin D prior to the 
addition of spirochetes. We found that cytochalasin D effectively blocked internalization 
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of spirochetes in PMs (Figure 12). This result is consistent with phagocytosis assays 
using B. burgdorferi and human monocytes or murine BMDM, as cytochalasin D has 
been used to inhibit the internalization of spirochetes in these cells (124, 147). Thus, we 
used cytochalasin D in our assays to estimate the background fluorescence from 
extracellular spirochetes adhered to macrophages, which in turn was subtracted to the 
total relative fluorescence of the experimental sample to obtain a corrected unit that was 
used as a surrogate marker of spirochetal ingestion by macrophages. Our fluorometric 
based phagocytosis assay showed the ospC mutant had approximately 75% higher 
phagocytosis by murine PMs than the wild-type and the ospC-complement strains 
(Figure 13A left). Based on our preliminary data using MOIs of 10:1 and 100:1, we 
found that an MOI of 100:1 had the greatest effect on phagocytosis of the ospC mutant 
and selected this MOI for the rest of our phagocytosis assays. We also found that 
phagocytosis was enhanced when using a different ospC mutant that was generated in B. 
burgdorferi strain 297 (202) (Figure 13A right). Flow cytometry also confirmed that the 
ospC mutant had approximately 70% higher uptake by murine PMs than the parental 
wild-type spirochete (Figure 13B). Additionally, we used immunofluorescent 
microscopy to count the number of GFP positive PMs during phagocytosis and found that 
the number of GFP positive events for PMs challenged with the ospC mutant was 
enhanced when compared to the wild-type 297 strain (Figure 14A-B). Together, these 
results suggest that OspC could have an anti-phagocytic function on murine macrophages 
as phagocytosis of OspC-expressing spirochetes was markedly reduced when compared 
to spirochetes lacking OspC.  
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Figure 12. Cytochalasin D prevents the uptake of B. burgdorferi strains. A). Murine 
PMs were preincubated for 30 min with or without 5 μg/ml cytochalasin D prior to the 
addition of GFP-expressing spirochetes (B31 strains). The numbers of spirochetes 
remaining after 2 h of incubation were determined using a microplate fluorometer as 
detailed in materials and methods. The relative fluorescence units of internalized (RFUi) 
spirochetes is determined by subtracting the fluorescence of unquenched, extracellular 
spirochetes (RFU ex from cytochalasin D treated cells) from the total fluorescence of the 
experimental well (RFU total from experimental samples). Values represent mean ± SEM 
from at least five experimental replicates used in a representative experiment.  
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Figure 13.  Abrogation of OspC enhances phagocytosis of B. burgdorferi by murine 
macrophages. A) Quantitation of phagocytosis of GFP-expressing wild-type spirochetes 
(B31 and 297-strains) by murine PMs determined using a microplate fluorometer. PMs 
were incubated with GFP-expressing spirochetes at an MOI of 100:1 for 2 h. The 
phagocytic index (PI) represented the fluorescence of intracellular bacteria phagocytosed 
by macrophages. Data are representative of 3 or 4 separate experiments with at least 4-5 
replicates per experiment. Values represent mean ± SEM. Comparisons among 
experimental groups were performed with one-way ANOVA followed by Dunnett’s post 
hoc test (*, P < 0.05; **, P < 0.005). B) Representative histograms of phagocytosis of 
B31-A3-gfp (grey solid line) and ospC-gfp (black solid line) spirochetes analyzed by flow 
cytometry. PMs were incubated with GFP-expressing spirochetes at an MOI of 100:1 for 
2 h, followed by washing and fixation prior to flow cytometric analysis. The black dotted 
line represents control uninfected cells. Percentage of phagocytosis is shown on the right. 
Data represent the percentage of GFP-expressing spirochetes phagocytosed by PMs 
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obtained from three separate experiments (Student’t test *, P < 0.05). Values are 
expressed as mean ± SEM.  
 
 
Figure 14. Enhanced uptake of GFP-expressing ospC mutant spirochetes by murine 
macrophages. A)  Fluorescence and bright field micrographs of PMs incubated with 
GFP-expressing wild-type (WT-297) or ospC mutant strains for 2 h at an MOI of 100:1. 
At the end of a 2 h incubation time, cells were washed twice with 1 x PBS and incubated 
with trypan blue for 5 min to quench extracellular fluorescence. Cells were imaged using 
an EVOS fl digital fluorescence microscope. Black arrows indicate GFP-positive PMs 
(merge images from middle panel, magnification x10) that were zoomed in bottom 
panels. B) Quantitation of phagocytosis is defined as the total number of GFP positive 
events counted from fluorescent micrographs using ImageJ as described in material and 
methods. Data are representative of 3 fields per experiment from two separate 
experiments. Values are expressed as mean ± SEM.  
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 We next examined whether OspC expression in spirochetes had an effect on 
phagocytosis by THP-1 macrophage-like cells. Similar to murine macrophages, the ospC 
mutant had significantly higher phagocytosis by THP-1 macrophage-like cells than the 
wild-type and the complement spirochetes (Figure 15A-B). In addition to macrophages, 
we further examined the role of OspC in phagocytosis of GFP-expressing spirochetes 
using neutrophil-like HL60 cells (PMN-HL60), since neutrophils are another type of 
professional phagocyte that can avidly phagocytose B. burgdorferi (133, 151). We found 
that uptake of the ospC mutant by PMN-HL60 cells was similar to the parental wild-type 
strain (Figure 16A-B), suggesting that OspC does not play a role in phagocytosis of B. 
burgdorferi by neutrophils. Taken together, our data suggest that OspC could have an 
anti-phagocytic property that reduces phagocytosis of B.burgdorferi strains by murine 
and human macrophages. 
 
Figure 15. Abrogation of OspC enhances phagocytosis of B. burgdorferi by human 
macrophage-like cells. A) Quantitation of phagocytosis of GFP-expressing spirochetes 
(B31) by THP-1 macrophage-like cells (PMA-treated THP1 cells) determined using a 
 76 
 
microplate fluorometer. THP-1 macrophage-like cells were incubated with GFP-
expressing spirochetes at an MOI of 100:1 for 2 h. The phagocytic index (PI) represented 
the fluorescence of intracellular bacteria phagocytosed by THP-1 macrophage-like cells. 
Data are representative of 3 or 4 separate experiment with at least 4-5 replicates per 
experiment. Values represent mean ± SEM. Comparisons among experimental groups 
were performed with one-way ANOVA followed by Dunnett’s post hoc test (*, P < 0.05; 
**, P < 0.005). B) Representative histograms of phagocytosis of B31-A3-gfp (grey solid 
line) and ospC-gfp (black solid line) spirochetes analyzed by flow cytometry.  THP-1 
macrophage-like cells were incubated with GFP-expressing spirochetes at an MOI of 
100:1 for 2 h, followed by washing and fixation prior to flow cytometric analysis. The 
black dotted line represents control uninfected cells. Percentage of phagocytosis is shown 
on the right. Data represent the percentage of GFP-expressing spirochetes phagocytosed 
by THP-1 macrophage-like cells obtained from three separate experiments (Student’t test 
*, P < 0.05). Values are expressed as mean ± SEM. 
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Figure 16. Uptake of B. burgdorferi by PMN HL60 cells is independent of OspC. A) 
Representative histograms of phagocytosis of B31-A3-gfp (grey solid line) and ospC-gfp 
(black solid line) spirochetes analyzed by flow cytometry. The black dotted line 
represents control uninfected cells. B) GFP-expressing spirochetes were incubated with 
PMN-HL60 cells at an MOI of 100 for 2 h, followed by washing and fixation prior to 
flow cytometric analysis. Data represent the percentage of GFP-expressing spirochetes 
phagocytosed by 1.25% DMSO-treated HL60 cells obtained from three separate 
experiments. Values are expressed as mean ± SEM.  
 
Scavenger receptor A and B mediates phagocytosis of B. burgdorferi independently 
of OspC  
 To date, conventional phagocytosis of B. burgdorferi has been shown to be 
mediated by different phagocytic receptors, including complement receptor-3 (137, 138), 
Fc receptors (132, 136), and the scavenger receptor Macrophage Receptor with 
Collagenous Structure (MARCO) (243). In addition, other members of the scavenger 
receptor family as well as the mannose receptor have been proposed to bind or participate 
in this process (125, 243, 244); however, their roles as phagocytic receptors are not fully 
understood. Because B. burgdorferi induces the expression of the class-A scavenger 
receptor family (CASR), including the scavenger receptor A I/II (SR-AI/II) and MARCO, 
when internalized by murine bone marrow-derived macrophages (243), we then 
examined whether this scavenger receptor family played a role in this enhanced 
phagocytosis of the ospC mutant (Figure 17A). To test this, murine PMs were 
preincubated with non-selective inhibitory ligands of CASR such as poly I and fucoidan 
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(245) before phagocytosis of spirochetes. Uptake of wild-type and ospC mutant 
spirochetes was substantially reduced in PMs treated with poly I and fucoidan at 400 
µg/ml and 500 µg/ml, respectively (Figure 17B-C). Treatment of PMs with fucoidan at 
100 µg/ml significantly reduced phagocytosis of the ospC mutant when compared to PMs 
incubated with the ospC mutant alone. However, OspC did not have an effect on 
phagocytosis of spirochetes in treated PMs as phagocytosis of the ospC mutant was 
higher than the wild-type strain even after CASR treatment (Figure 17D). Representative 
RFU of internalized spirochetes (RFUi) values from a single experiment are shown in 
figure 17D.  
 
 
Figure 17. Class-A scavenger receptor blockers reduces phagocytosis of GFP-
expressing B. burgdorferi strains independently of OspC. Fluorescence was 
determined using a microplate fluorometer after 2 h as detailed in materials and methods. 
 79 
 
The phagocytic index (PI) represented the fluorescence of intracellular bacteria 
phagocytosed by murine peritoneal macrophages (PMs). A) Phagocytosis of GFP-
expressing spirochetes (B31-strains) by PMs at an MOI of 100:1. B-C) Murine PMs were 
pretreated with nonselective CASR blockers poly I (at 400 ug/ml) and fucoidan (at 100 
µg/ml or 500 µg/ml), and the phagocytosis of GFP-expressing spirochetes at an MOI of 
100:1 was quantified by fluorometry. Comparison of % of phagocytosis of treated PMs 
relative to untreated controls (black dotted line). D) Representative RFUi values of 
phagocytosed spirochetes by CASR treatment. Data are representative of 3 or 4 separate 
experiment with at least 4-5 replicates per experiment. Values represent mean ± SEM. 
Comparisons among experimental groups were performed with one-way ANOVA 
followed by Dunnett’s post hoc test (*, P < 0.05; **, P < 0.005). 
 
 To demonstrate that CASR was indeed involved in phagocytosis of spirochetes, 
we next preincubated PMs with a monoclonal antibody (ED31, 12 µg/ml) against 
MARCO, a class A scavenger receptor, before measuring phagocytosis. MARCO 
receptor was selected to block CASR-mediated phagocytosis since uptake of B. 
burgdorferi has shown to be reduced by MARCO deficient macrophages (243). Prior to 
these experiments, as Fc receptors have been shown to mediate phagocytosis of 
nonopsonized and opsonized spirochetes (137, 138), we preincubated PMs with 2.4G2 
antibodies to block nonspecific Fc receptor-mediated interactions that might occur during 
phagocytosis either directly with spirochetes or indirectly with antibodies bound to 
spirochetes. Representative data from our phagocytosis assays showed that blocking Fcγ 
receptor did not alter phagocytosis of spirochetes as RFUs of internalized spirochetes 
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(RFUi) from 2.4G2-treated PMs were similar to the values shown by untreated PMs 
(Figure 18). In our anti-MARCO blocking experiments, we found that blocking MARCO 
significantly reduced MARCO-mediated phagocytosis of wild-type and ospC mutant 
spirochetes (Figure 19A), and this effect was independent of the expression of OspC in 
spirochetes Figure 19C). RFUi values from a representative experiment are shown in 
figure 19C. Together, our CASR blocking experiments support the notion that members 
of the class A family of scavenger receptors participate in phagocytosis of B. burgdorferi 
in mouse macrophages. 
 
Figure 18. Pretreatment of murine PMs with Fc receptor blocking antibodies does 
not alter phagocytosis of non-opsonized GFP-expressing spirochetes. A) 
Representative RFUi values of phagocytosed spirochetes by 2.4G2 treatment. Murine 
PMs were preincubated for 30 min with or without 2.4G2 supernatants containing 
antibodies to specifically block mouse Fcγ receptor prior to the addition of GFP-
expressing spirochetes (B31 strains). The numbers of spirochetes remaining after 
phagocytosis for 2 h were determined using a microplate fluorometer and RFUi was 
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calculated as detailed in materials and methods. Data are representative of 3 separate 
experiments with at least 4 replicates per experiment. 
 
 
Figure 19. MARCO and CD36 mediates phagocytosis of GFP-expressing B. 
burgdorferi strains independently of OspC. The phagocytic index (PI) represented the 
fluorescence of intracellular bacteria phagocytosed by murine peritoneal macrophages 
(PMs) at an MOI of 100:1. PMs were pretreated with 2.4.G.2 antibodies that block Fcγ 
receptor as detailed in materials and methods. A) PMs were treated with rat anti-mouse 
directed against MARCO or an isotype control at 12 µg/ml, and the phagocytosis (MOI 
100 for 2 h) of GFP-expressing spirochetes was quantified by fluorometry. B) PMs were 
treated with rat anti-mouse directed against CD36 or an isotype control at 50 µg/ml, and 
the phagocytosis (MOI 100:1 for 2 h) of GFP-expressing spirochetes was quantified by 
fluorometry. Comparison of % of phagocytosis of treated PMs relative to untreated 
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controls (black dotted line). C-D) Representative normalized RFUi values of 
phagocytosed spirochetes by antibody treatments. Data are representative of 3 or 4 
separate experiments with at least 4 replicates per experiment. Values represent mean ± 
SEM. Comparisons among experimental groups were performed with one-way ANOVA 
followed by Dunnett’s post hoc test (*, P < 0.05; **, P < 0.005). 
 
 The data above suggest that OspC production did not play a major role in 
scavenger receptor A-mediated phagocytosis. Therefore, we focused our efforts in 
studying another phagocytic receptor that recognizes lipoproteins and internalizes 
bacterial pathogens. One such phagocytic receptor is CD36, a class B scavenger receptor 
that mediates adhesion and internalization of Gram-positive and -negative bacteria and 
TLR2 ligands (246, 247). Furthermore, several studies have indicated that CD36 also 
cooperates with TLR2 dependent signaling responses associated with bacterial 
recognition (246). Thus, we examined whether CD36 was involved in this different 
uptake between wild-type and the ospC mutant by macrophages. Fcγ-treated PMs were 
preincubated with anti-CD36 before measuring phagocytosis of B. burgdorferi strains as 
described above. We found that treatment of PMs with anti-CD36 antibodies significantly 
reduced the uptake of both the wild-type and the ospC mutant strain (Figure 19B). OspC 
also did not appear to play a role in CD36-mediated phagocytosis by PMs as 
phagocytosis of the ospC mutant was higher than the wild-type strain even after CD36 
treatment (Figure 19D). RFUi values from a representative experiment are shown in 
figure 19D. 
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Expression of cytokines by murine peritoneal macrophages infected with wild-type 
or the ospC mutant 
 Seminal studies demonstrated that B. burgdorferi lipoproteins are recognized by 
TLR-2/1 heterodimers on the surface of phagocytes inducing activation of NF-kB and the 
subsequent production of cytokines (118, 119). Recent studies have also proposed that 
the release of spirochetal byproducts within the phagosomal compartment of 
monocytes/macrophages are recognized by intracellular TLRs leading to the production 
of cytokines (120, 248). Thus, we next examined whether the production of OspC in 
spirochetes was associated with an alteration in cytokine expression by murine PMs. To 
test this, murine PMs were infected with the wild-type strain or the ospC mutant at an 
MOI of 100:1 for 2, 6, and 24 h. RNA was extracted from infected PMs to quantify the 
mRNA levels of TNF-α, IL-1β, and IL-10 as these cytokines are expressed during 
infections of monocytes/macrophages with B. burgdorferi (120, 170). Our findings 
showed that the mRNA levels of these cytokines was not affected by OspC expression in 
spirochetes, as there were no significant differences in the mRNA level produced by PMs 
infected with the wild-type and the ospC mutant at any of the time points post-challenge 
(Figure 20). Transcripts of these cytokines from a representative experiment are shown 
in figure 20. We observed that the highest level of TNF-α occurred after 2 h post-
infection in PMs challenged with the ospC mutant while the expression of this cytokine 
was lowered at 6 h post-infection. Conversely, we noted that the highest level of TNF-α 
occurred 6 h post-infection in PMs challenged with the wild-type strain while the 
expression of this cytokine was lowered at 2 h post-infection. Cytokine expression in 
infected PMs were nearly at the basal level similar to unstimulated PMs at 24 h. 
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Figure 20. Expression of TNF-α, IL-1β, and IL-10 after infection of murine 
peritoneal macrophages by wild-type (B31-A3) and ospC mutant spirochetes. mRNA 
levels of TNF-α, IL-1β, and IL-10 were determined from control uninfected cells and B. 
burgdorferi-infected PMs (MOI of 100:1) by RT-PCR after 2, 6 and 24 h of incubation. 
The data were normalized to the housekeeping gene β-actin and are expressed as the fold 
difference compared to unstimulated cells. Data are representative of 3 separate 
experiments. Values represent mean ± SEM. Comparisons of B31-infected and ospC-
infected PMs were performed using paired Student’s t test. 
 
The ospC mutant can establish infection when inoculated in mice with a high dose 
 Our in vivo data above showed that the ospC mutant cannot establish infection 
using a standard (103 spirochetes/mouse) and an intermediate inoculum (105 
spirochetes/mouse). We also attempted to infect immunocompetent and immunodeficient 
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mouse strains with a high inoculum (106 spirochetes/mouse) of the ospC mutant. Groups 
of C3H/HeN NODSCIDg, and SCID mice were injected with either wild-type B31-A3 or 
the ospC mutant with an inoculum of 106 spirochetes per mouse using BSK-II medium as 
vehicle. As comparison for SCID mice, groups of SCID mice were also challenged with 
wild-type or the ospC mutant using PBS buffer as vehicle. Unexpectedly, we observed 
that when inoculated in the skin with a high dose, the ospC mutant was able to establish 
infection (Table 7) in different mouse strain backgrounds. ospC mutant reisolates were 
analyzed by immunoblotting to confirm that these spirochetes were indeed not expressing 
OspC (Figure 21A). Infected immunodeficient mice developed joint swelling and 
showed evidence of arthritis in tibio-tarsal joints (Figure 21B). These findings suggest 
that high doses of inoculation can overcome the survival defect of the ospC mutant at the 
skin site of inoculation in mice. 
Table 7. Infectivity of wild-type B. burgdorferi (B31-A3) and the isogenic ospC 
mutant in NODSCIDg, SCID, and C3H/HeN mice when inoculated with a high dose.  
* Spirochetes were inoculated intradermally (i.d.) in BSK or PBS and intraperitoneally in 
PBS as vehicles. 
^ All mice were euthanized at either 3 weeks post-inoculation (PI). Isolation of 
spirochetes were attempted from skin-site of inoculation, ear pinna, tibio-tarsal joint, 
 
 
Route of 
Inoculation*
Dose Bb 
strain 
Vehicle 3 weeks 
PI^ 
NODSCIDg i.d. 106 B31-A3 BSK 3/3 
NODSCIDg i.d. 106 ospC BSK 3/3 
SCID i.d. 106 B31-A3 BSK 3/3 
SCID i.d. 106 ospC BSK 6/9 
Balb/c scid i.d. 106 ospC BSK 1/6 
C3H/HeN i.d. 106 B31-A3 BSK 3/3 
C3H/HeN i.d. 106 ospC BSK 3/6 
SCID i.d. 106 B31-A3 PBS 3/3 
SCID i.d. 106 ospC PBS 3/3 
SCID i.p. 106 B31-A3 PBS 3/3 
SCID i.p. 106 ospC PBS 2/3 
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heart base and spleen.  Culture results expressed as number of mice infected/number of 
mice tested. Infectivity experiments were conducted in 3 separate trials. 
 
 
 
Figure 21. The ospC mutant can infect SCID mice and cause arthritis when 
inoculated at a high dose. Tibio-tarsal joints from SCID mice were collected 4 weeks 
post-challenge with either wild-type or the ospC mutant spirochetes (106 
spirochetes/mouse) and subjected to cultivation for re-isolation of spirochetes or for 
histological analyses. A) Immunoblot analysis confirming that the spirochetes re-isolated 
from mice infected with the ospC mutant remained lacking OspC. Re-isolated spirochetes 
were cultivated in the standard BSK-II medium at 37°C and harvested at the stationary 
growth phase, and subjected to immunoblotting analysis using a mixture of monoclonal 
antibodies against FlaB (control) and OspC. B) Macroscopic observation of ankle 
thicknesses in SCID mice infected with ospC 4 weeks post-intradermal inoculation with 
106 spirochetes (top panel). Representative images of H&E-stained histological sections 
from tibio-tarsal joints of SCID mice 4 weeks post-challenge (bottom panel, 
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magnification, ×2.5). Tibio-tarsal joints exhibited severe periarticular inflammation 
involving ligaments and tendon sheaths (black arrows) with cellular infiltrates primarily 
composed by macrophages with few neutrophils. 
 
Part II- B. burgdorferi EF-Tu is an immunogenic antigen during Lyme borreliosis 
B. burgdorferi EF-Tu is recognized by mouse and human sera during infection 
 EF-Tu has been shown to be an immunogenic protein during active infection and 
after exposure for a number human and animal bacterial pathogens (205, 249-251). To 
determine whether B. burgdorferi EF-Tu is immunogenic during infection in mice, sera 
from infected mice with Lyme borreliosis were tested for reactivity to purified rEF-Tu 
(Figure 22A). We found that antibodies to rEF-Tu were detectable in sera of infected 
mice as early as 2 weeks after needle inoculation of mice with in vitro-cultivated B. 
burgdorferi. Seroreactivity to rEF-Tu was detectable even at 6 weeks or 11 weeks (data 
not shown) post-infection (Figure 22B), suggesting that B. burgdorferi anti-EF-Tu 
antibodies are maintain after 2 months of infection in mice. This result prompted us to 
evaluate if sera from Lyme disease patients could be reactive to rEF-Tu.  We found that 
70% of samples tested (7 positives out 10 patients tested) were reactive to rEF-Tu 
(Figure 22C). Seroreactivity to rEF-Tu was detected in samples from seropositive 
patients with different clinical manifestations associated with Lyme disease, including 
erythema migrans, arthritis and/or neurologic symptoms. Four samples exhibited strong 
reactivity to rEF-TU and were also seropositive by ELISA and Western blot with IgM 
and IgG antibodies against B. burgorferi antigens. Two samples that exhibited strong 
reactivity to rEF-Tu were also seropositive by ELISA and Western blot for IgM 
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antibodies against B. burgorferi antigens. One sample was also reactive to rEF-TU and 
tested positive by ELISA and Western blot for IgG when blotted against B. burgorferi 
antigens. Together, these results indicate that B. burgdorferi rEF-Tu can be recognized by 
antibodies during natural and artificial Lyme infection in mammals. 
 
Figure 22. Serologic reactivity of sera from infected mice and selected Lyme disease 
patients to recombinant EF-Tu. A) SDS-PAGE results from purified recombinant EF-
Tu protein (~15 ug loaded). Predicted size for B. burgdorferi EF-Tu is 43kDa. B) 
Appearance of antibodies against rEF-Tu during the course of infection in C3H/HeN 
mice after needle inoculation of mice with B. burgdorferi strain 5A4NP1. Recombinant 
EF-Tu (~ 500 ng/strip) was subjected to SDS-PAGE. Nitrocellulose strips were 
immunoblotted with 1:600 dilutions of murine infectious sera collected at various 
intervals post-challenge. The lane at the right (N^) is a strip probed with sera from naïve 
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mice. The lane labeled HS* is a strip probed with mouse antiserum against rEF-Tu (αEF-
Tu, 1:10000 dilution). C) Serologic reactivity of sera from Lyme disease patients to rEF-
Tu. Nitrocellulose strips (~ 500 ng rEF-Tu/strip) were immunoblotted with 1:100 
dilutions of human sera. Panels A-B are strips probed with sera from healthy controls 
from areas that are non-endemic to Lyme disease.  Panels C to F are representative results 
from strips probed with sera from 4 different Lyme disease patients. Data are 
representative of two separate experiments. 
 
Active immunization of mice with rEF-Tu is not protective against artificial and 
tick-borne B. burgdorferi infection 
 The observation above showing that immune sera from infected mice contain 
antibodies against rEF-Tu led us to assess whether immunization of mice with rEF-Tu 
could elicit protective immunity against B. burgdorferi infection. Groups of four to six 
mice were actively immunized with rEF-Tu or Freund’s adjuvant alone (control), 
antibody titers were verified, and then mice were intrademally challenged with wild-type 
B. burgdorferi strain 5A4NP1. Cultures from ear-punch biopsies showed that all mice, 
regardless of their vaccination status, were culture positive after 2 weeks post-challenge 
(Table 8). Spirochetes were also cultured from tibio-tarsal joints and hearts in mice from 
both treatment groups at either 2 or 5 weeks post-challenge. In addition, we used real-
time qPCR to quantify flaB DNA in joint tissues after 2 weeks of needle inoculation of 
spirochetes. Our qPCR results showed no significant differences in the bacterial load of 
mice treated with rEF-Tu in comparison to control mice (Figure 23A). We next 
challenged a second group of immunized mice and controls using infected unfed nymphs 
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to determine the role of EF-Tu antibodies during natural infection. Similar to needle-
inoculated infected mice, we found that spirochetes were cultured from every single 
tissue from both treatment groups after 2 weeks of tick feeding (Table 8). These data 
indicate that immunization of mice with rEF-Tu does not play a role in the control of B. 
burgdorferi infection. 
Table 8. Active immunization of mice with rEF-TU did not elicit a protective 
response after B. burgdorferi challenge. 
Method of inoculation  Group  Culture result^ 
 
Needle  Adjuvant  4/4 
 Adjuvant + rEF-Tu  6/6 
Nymphal ticks Adjuvant  2/2 
 Adjuvant + rEF-Tu  2/2 
 
^ Mice were euthanized at either 2 or 5 weeks post-challenge. Isolation of spirochetes 
were attempted from ear pinna, tibio-tarsal joint, and heart base.   
 
 To determine whether immunization of mice with rEF-Tu could influence 
acquisition of spirochetes by ticks, naïve larvae were fed on a group of immunized or 
control mice that were infected with B. burgdorferi as described above. The spirochete 
load from fully engorged larvae was then assessed by qPCR after 72-96 h of feeding. We 
found no significant differences in spirochete loads in fed larvae from immunized and 
control groups at day 34 post-infection (Figure 23B). In addition, we also did not 
observe, by IFA, noticeable differences in the number of spirochetes in tick-smears 
collected from both treatment groups (data not shown). Together, these results indicate 
that EF-Tu antibodies did not interfere with B. burgdorferi acquisition by ticks. 
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Figure 23. Active immunization of mice with rEF-Tu does not affect spirochetal 
loads in tibio-tarsal joints and interfere with acquisition of spirochetes by tick 
larvae. A) qPCR results showing copies of B. burgdorferi flaB relative to the copies of 
mouse nidogen.  Samples contained joint DNA from groups of mice treated with either 
adjuvant alone or adjuvant + rEFTU at day 14 post-infection. B) qPCR analyses of 
spirochete load in fed larvae. qPCR for the B. burgdorferi flaB gene was performed with 
DNA extracted from fed larvae (9-18 ticks for each group). The number of copies of the 
flaB gene compared to the number of copies of the tick actin gene. Samples contained 
tick DNA from mice treated with either adjuvant alone or adjuvant + rEF-Tu at day 34 
post-infection. Data are representative of two separate experiments. Differences between 
mice immunized with rEF-Tu and controls was analyzed using a Student t test (P ≤ 0.05).   
 
B. burgdorferi EF-Tu is not surface exposed 
 Since rEF-Tu binds to antibodies present in sera from infected individuals, this 
led us to hypothesize that a fraction of EF-Tu is surface exposed in the outer membrane 
of B. burgdorferi.  Recent studies have also revealed novel functions of EF-Tu since it is 
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associated with the cell surface in several pathogenic and commensal bacteria (196, 197, 
200). To investigate whether EF-Tu is a membrane-associated protein in B. burgdorferi, 
we first examined, by IFA, the ability of intact and permeabilized B. burgdorferi to bind 
antibodies directed against EF-Tu. Monoclonal antibodies directed against the 
periplasmic FlaB protein and the surface-exposed OspA lipoprotein of B. burgdorferi 
were used as controls. Our IFA results showed that antibodies directed against EF-Tu 
recognize this protein in permeabilized spirochetes (Figure 24A, top panel). Both FlaB 
and OspA were also readily detected in fixed, permeabilized spirochetes. However, we 
found that unfixed, non-permeabilized spirochetes were unable to bind anti- EF-Tu 
antibodies (Figure 24A, bottom panel). FlaB was also inaccessible, while OspA were 
readily detected in intact spirochetes (Figure 24A, bottom panel). We then reasoned that 
EF-Tu could be expressed at different levels in in vitro-cultivated B. burgdorferi, and this 
would explain the inaccessibility of anti-EF-Tu antibodies since EF-Tu was not 
abundantly expressed on the surface of viable wild-type spirochetes at the time point of 
this assay. Thus, we generated a B. burgdorferi strain (B31-A3/PflaB-eftu-HA) that 
constitutively expresses EF-Tu (Figure 25). Our IFA experiments provided evidence that 
endogenous EF-Tu and HA-tagged EF-Tu were inaccessible to anti-EF-Tu and anti-HA 
antibodies in intact B31-A3/PflaB-eftu-HA spirochetes (data not shown). Taken together, 
these results suggest that EF-Tu is not expressed on the outer membrane of B. 
burgdorferi.  
 Previous studies have indicated that outer surface proteins, such as OspA, can 
hinder access of antibodies to epitopes of other integral membrane proteins of B. 
burgdorferi (252, 253). To address this possibility, we then examined whether EF-Tu was 
 93 
 
susceptible to in situ proteolysis using proteinase K. This protease can degrade surface-
exposed proteins in B. burgdorferi, whereas subsurface proteins are protected from 
proteolysis. Our results showed that the bulk of OspA in intact B31-A3/PflaB-eftu-HA 
spirochetes was degraded by high concentrations (100-200 ug/ml, Figure 24B) of 
proteinase K while neither FlaB nor EF-Tu (Figure 24B) in intact spirochetes was 
affected by high concentrations of proteinase K. This protease was also unable to digest 
EF-Tu from intact wild-type B31-A3 spirochetes (Figure 24B). These results further 
demonstrate that EF-Tu is not a surface exposed protein in B. burgdorferi.   
 
Figure 24. EF-Tu does not localize in the outer membrane of B. burgdorferi. A) 
Indirect immunofluorescence of fixed and unfixed B. burgdorferi strain B31-A3. 
Spirochetes were fixed (top panel) in acetone as described in material and methods. Fixed 
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and unfixed spirochetes (bottom panel) were probed with monoclonal antibodies directed 
against OspA or FlaB and mouse polyclonal directed against EF-Tu. Fluorescein 
isothiocyanate (FITC) - conjugated goat anti-mouse IgG was used to detect bound 
antibodies (Bar, 2-20 µm). B) Cell lysates from wild-type B. burgdorferi strain B31-A3 
(WT) was incubated with either PBS alone (lane −) or PBS containing 200 µg/ml 
proteinase K (lane +). The treated cells were then subjected to immunoblot analysis using 
a combination of antibodies against OspA, FlaB, and EF-Tu. C) SDS-PAGE (left panel) 
and immunoblot analysis (right panel) of the effect of proteinase K on EF-Tu proteins 
from B31-A3/PflaB-eftu-HA that constitutively expresses EF-Tu. Intact cells were 
incubated for 1 h with 25, 50, 100 or 200 µg/ml of proteinase K. After being washed, the 
cells were subjected to SDS-PAGE stained with Coomassie blue, and immunoblots of the 
cell lysates were probed using a mixture of antibodies against OspA, FlaB, and EF-Tu. 
OspA, a surface-localized lipoprotein, served as a positive control, and FlaB served as a 
negative control. Data are representative of four separate experiments. 
 
 
 
ORF123 
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Figure 25. Transformation of B. burgdorferi strain B31-A3 to constitutively express 
HA-tagged EF-Tu (B31-A3/PflaB-eftu-HA). A) Construction of pYY003 shuttle vector. 
EF-Tu-HA and Kanamycin (Kan) are under the control of a constitutive Borrelia 
promoters PflaB and PflgB, respectively (ColE1 = E. coli origin of replication and 
ORF123 = plasmid replication genes from cp9 of B. burgdorferi). B) Confirmation of 
HA-tagged EF-Tu production by immunoblotting. Wild-type B31-A3 strain (lane 1) and  
B31-A3/PflaB-eftu-HA clone (lane 2) were grown to mid-log phase in BSK-II medium, 
harvested by centrifugation and subjected to SDS-PAGE stained with Coomassie blue 
(left) and immunoblotting (right). Samples were probed with a mixture of FlaB and 
HA.11 monoclonal antibodies. 
 
EF-Tu localizes in cytoplasm and is a protoplasmic cylinder-associated protein in B. 
burgdorferi 
 To further examine the cellular localization of EF-Tu, we next performed Triton 
X-114 (TX-114) phase partitioning studies with B. burgdorferi cells to separate fractions 
based on their amphiphilic properties. As shown in Figure 26A, EF-Tu partitioned 
exclusively into the soluble aqueous (non-membrane-enriched) fractions, suggesting that 
they are cytoplasmic proteins. As expected, OspA, a known outer surface lipoprotein, 
was found in the detergent (membrane-enriched) fractions (Figure 26A).  
 Because B. burgdorferi is able to form OMVs that contain immunogenic surface 
and cytoplasmic proteins (193, 219, 254), we then assessed whether EF-Tu could be part 
of the protein cargo that is released in OMVs from spirochetes. To test this, intact 
spirochetes were separated into two major fractions, outer membrane vesicles and PC 
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inner membrane associated proteins, which were then subjected to immunoblot analyses 
with anti-EF-Tu and anti-OspA antibodies. We found that EF-Tu protein was primarily 
associated with the PC inner membrane enriched fractions; however, small quantities of 
EF-Tu were detected in OMVs fractions (Figure 26B). As expected, OspA was 
predominantly detected in the OMVs fractions (Figure 26B). Collectively, our data 
shows that EF-Tu localizes primarily in the cytoplasm, associates with PC structures, and 
is detected in small quantities in OMVs.  
 
Figure 26. A fraction of B. burgdorferi EF-Tu is associated with protoplasmic 
cylinder fractions. A) EF-Tu is in the soluble fraction.  Immunoblot analysis of whole-
cell phase partitioning. The detergent-enriched (Det) and aqueous-enriched (Aq) phases 
were immunoblotted with antibodies against EF-Tu or OspA, which is known to localize 
in the detergent phase. B) EF-Tu is associated with protoplasmic cylinder fractions. B. 
burgdorferi PC and OMVs were separated by sucrose density gradient centrifugation and 
equal amounts of protein from two subcellular fractions were separated by SDS-PAGE, 
and immunoblotted with antibodies directed against EF-Tu or OspA. These antibodies 
were also immunoblotted against wild-type (WT, right lane) B. burgdorferi whole-cell 
lysates. 
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CHAPTER V: DISCUSSION 
Part-I Role of B. burgdorferi OspC during Lyme borreliosis 
 Since the discovery of Borrelia burgdorferi in 1975 as the sole etiological agent 
of Lyme disease, the number of Lyme disease cases have exponentially increased to the 
point that this tick-borne illness has become a significant public health problem in 
endemic areas of United States. During these past three decades, considerable research 
efforts have enhanced the understanding on the phylogenetic diversity, molecular 
biology, pathogenesis, and host interactions of B. burgdorferi. The development of 
genomic tools and genetic manipulation of B. burgdorferi have contributed to the 
understanding of genes involved during infection within the tick and mammalian host. 
However, most of the genes encoded by B. burgdorferi plasmids (~535 putative genes)  
and about a third of the genes encoded by its chromosome (~30%) are unique and most of 
them have unknown biological functions (60, 61). One characteristic feature of the  
B. burgdorferi genome is that it encodes numerous surface lipoproteins that are essential 
for the maintenance of this pathogen in the enzootic life cycle (14). The surface 
lipoprotein OspC is a major virulence factor that is induced when ticks start feeding on 
the mammalian host (171) and  is required for B. burgdorferi to establish mammalian 
infection (49, 64, 65). However the precise function of OspC during the early stage of 
infection remains unclear.  
 Previous studies have indicated that OspC could exhibit numerous properties that 
could promote dissemination and survival during early infection in the mammalian host. 
OspC could serve as an adhesin to bind host plasminogen (89, 180, 255), suggesting that 
OspC-expressing spirochetes utilize the plasminogen/plasmin system to facilitate tissue 
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invasiveness within the host. Additionally, OspC may bind to other mammalian derived 
factors using a putative small ligand-binding domain (known as LBD1) that was 
demonstrated to play a critical role in survival of spirochetes during the initial stage of 
infection (179). In a demonstration of the versatility of this protein, OspC also binds to 
tick salivary proteins, such as Salp15, which is a major immunosuppressive protein in 
tick saliva that seems to protect B. bugdorferi from host defenses (111, 256-258). 
Evidently, the ability of OspC to bind multiple ligands contributes to the difficulty in 
defining the role of OspC during infection. 
 In addition, previous studies have proposed that OspC directly protects 
spirochetes against innate immunity during the early stage of mammalian infection (176, 
183); however, the mechanism for how OspC contributes to such a function had not been 
elucidated. In this dissertation, we provided evidence that spirochetes lacking OspC are 
cleared by phagocytes at the skin-site of inoculation in SCID mice, whereas wild-type 
spirochetes remain fully infectious in vivo, suggesting that OspC protects B. burgdorferi 
from being recognized by phagocytes during early infection in the murine host. We 
further showed that OspC reduced the phagocytosis of spirochetes by murine and human 
macrophages. Together, our in vivo and in vitro findings suggest that OspC protects 
spirochetes against skin phagocytes, as a potential immune evasion strategy to survive 
during early stages of mammalian infection. Findings from our studies could be used for 
future investigations to understand the interaction of other B. burgdorferi surface proteins 
with skin phagocytes as the mouse skin has been proposed as an important natural barrier 
that selects for B. burgdorferi populations with increased fitness in the host (106, 259).  
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The ospC mutant establishes infection in phagocyte depleted mice 
 B. burgdorferi infection elicits both innate and adaptive immune responses to 
control spirochetal burden in the murine host (32, 39).  Previous work has shown that the 
OspC-deficient spirochetes generated from different B. burgdorferi strain backgrounds 
cannot establish infection in both immunocompetent and SCID mice, indicating that 
adaptive immunity does not play a major role in eliminating the ospC mutant in vivo (49, 
177). SCID mice have elevated levels of lytic complement activity and normal levels of 
NK cell activity (240). Thus, we further investigated NODSCIDg mice since they lack 
not only adaptive immunity, but also lytic complement, and NK cells, and also have 
impaired cytokine signaling due to the lack of interleukin 2 receptor common gamma 
chain (IL-2Rγnull) (239). Our results showed that the ospC mutant also was not able to 
establish infection in NODSCIDg mice when inoculated at the standard dose (103 
spirochetes per mouse). The same inoculum of ospC mutant spirochetes cannot cause 
infection in C3H/HeN and SCID mice, which is what we observed in our infectivity 
experiments using these mouse strains (49, 64, 65, 99). Our findings suggest that the lytic 
complement and NK cells do not play a major role in clearance of the ospC mutant in 
vivo. This data is consistent with a previous report by Bockenstedt et al. (112), showing 
that the fifth component of complement is not required for protection and disease 
progression of wild-type B. burgdorferi infection in C5-deficient mouse strains. Our 
results are also consistent with findings from a previous report showing that depletion of 
NK cells did not have a major effect on B. burgdorferi burden and dissemination in 
arthritis-resistant and -susceptible mouse strains (169). Another potential insight from our 
findings is that opsonic phagocytosis mediated by Fc receptors on phagocytes are not 
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involved in the clearance of the ospC mutant in vivo, as ospC-deficient spirochetes could 
not establish infection in 4-6 week old NODSCIDg and SCID mice that lack functional T 
and B cells and have no detectable immunoglobulins at this age (260). 
 We then focused on professional phagocytes as one of the primary target cells for 
our depletion studies, as mononuclear phagocytes were reported  to infiltrate the skin-site 
of inoculation in mice (99) and neutrophils were elevated in circulation within the first 
week of B. burgdorferi infection in mice in our preliminary studies. Our result showed 
that the ospC mutant was cleared within the first 48 h post-challenge in mice treated with 
anti-Ly6G antibody, a method commonly used for neutrophil depletion. Although 
previous reports showed that neutrophils can effectively control spirochetal burden 
during infection (261, 262), our data suggest that the neutrophil is not the major factor in 
clearing the ospC mutant at the skin-site of inoculation. In contrast, we found that 
depletion of phagocytes at the skin site of inoculation in SCID mice allowed the ospC 
mutant to establish infection and dissemination, suggesting that phagocytes play an 
important role in clearing the ospC mutant. This finding suggest that B. burgdorferi 
employs OspC to evade phagocyte killing at the skin-site of infection. We also observed 
an increased spirochetal burden of wild-type B. burgdorferi in joints of clodronate-treated 
SCID mice. This observation is consistent with the notion that phagocytes such as F4/80+ 
macrophages are important in controlling the wild-type B. burgdorferi burden in cardiac 
and joint tissue of infected mice (39, 181).  
 Although depletion of F4/80+ phagocytes by clodronate liposome treatment is a 
widely used approach to study macrophage functions (263), our study did not rule out the 
possibility that other F4/80+ phagocytes such as naïve epidermal Langerhans cells could 
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be affected by this treatment and subsequently contributed to the clearance of the ospC 
mutant (236, 264). It is also possible that macrophage apoptosis induced by clodronate 
liposome treatment may have altered the innate cell homeostasis (265, 266), and 
subsequently created a permissive environment which allowed the ospC mutant to 
survive at the skin-site of inoculation. However, our data showed that clodronate 
treatment did not alter leukocytes and neutrophil numbers in our experiments, suggesting 
that the survival of the ospC mutant upon clodronate treatment was unlikely due to a 
dramatic alteration of innate cell homeostasis.  
B. burgdorferi OspC decreases macrophage phagocytosis 
 Previous studies have shown that human macrophages and murine peritoneal and 
bone marrow-derived macrophages can efficiently ingest and kill B. burgdorferi (155, 
267). In our phagocytosis assays, we observed significantly higher phagocytosis of the 
ospC mutant than wild-type spirochetes by murine PMs or THP-1 macrophage-like cells, 
using two independent B. burgdorferi strains. This increased phagocytosis may result in 
the clearance of the ospC mutant at the skin-site of inoculation during the first 48 h post-
infection as previously reported by other investigators (64, 268). Similarly to our 
findings, a previous report showed that another outer membrane lipoprotein such as OspB 
could have an antiphagocytic property against human neutrophils in vitro (269); however, 
the biological relevance of this finding is controversial, as this surface lipoprotein is 
rarely expressed by B. burgdorferi during mammalian infection (76, 171). In contrast, 
Lmp1, another outer membrane protein that is highly expressed during early mammalian 
infection, did not exhibit an antiphagocytic property in murine BMDM, as phagocytosis 
did not differ between  wild-type and lmp1 mutant spirochetes (270). Instead, B. 
 102 
 
burgdorferi Lmp1 appeared to play a role in evasion of adaptive immunity in the murine 
host (270). Thus, our findings suggest that OspC could directly protect B. burgdorferi 
from phagocytosis by mouse and human macrophages.  
 Because OspC has been previously proposed to bind tick salivary proteins during 
early infection (89, 110), another possible interpretation of our findings is that spirochetes 
lacking OspC are more susceptible to killing by phagocytes at the skin-site of the tick bite 
because the ospC mutant may have a reduced ability to bind tick salivary proteins relative 
to the wild-type strain in vivo. It is well-accepted that tick salivary proteins provide a 
survival advantage for spirochetes in the murine host (89, 111, 178). In vitro studies also 
showed that tick salivary proteins decreased the ability of neutrophils to adhere to and kill 
spirochetes (271), suggesting tick proteins limit the interaction of spirochetes with 
neutrophils during early Lyme borreliosis. Future studies are needed to determine the 
contribution of OspC-specific tick ligands such as Salp15 in macrophage phagocytosis of 
wild-type and ospC mutant spirochetes.  
 Of note, we observed a high phagocytic activity of THP-1 cells against B. 
burgdorferi, which is somewhat different from a previous study showing that Vitamin 
D3-treated THP-1 cells have poor phagocytic capacity for B. burgdorferi (272). One 
possible explanation was that we used PMA to activate and differentiate THP-1 cells into 
macrophage-like cells (273, 274). PMA differentiated THP-1 cells have been 
demonstrated to exhibit higher phagocytic activity and adherence and different 
expression of surface receptors than Vitamin D3 differentiated THP-1 cells (222, 274).  
 Phagocytosis of B. burgdorferi by macrophages involves several phagocytic 
receptors that are known to increase the efficiency of internalization of spirochetes, as 
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well as Toll-like receptors that activate MyD88-dependent or -independent mechanisms 
to enhance phagocytosis (29, 30, 76). The scavenger receptor MARCO mediates 
phagocytosis of B. burgdorferi in mouse BMDM, and expression of this receptor was 
upregulated upon Borrelia stimulation in a MyD88-dependent manner (30). In our 
studies, we showed that nonselective CASR blockers and anti-MARCO antibody reduced 
the uptake of wild-type and ospC mutant spirochetes by murine PMs, suggesting that the 
class A family of scavenger receptors (including MARCO) plays a role in phagocytosis 
of B. burgdorferi. These results are in agreement with previous studies showing that 
blocking scavenger receptor-A I/II (SR-A I/II) and MARCO reduces phagocytosis of 
bacteria by murine PMs (47, 77), which are known to express CASR receptors. Although 
much is known about the structure of CASR and their ligands (60), the mechanisms for 
how CASR convey signals after microbial-ligand binding are not well understood (78). 
Recent studies proposed that SR-A/MARCO modulate TLR- and NOD-like receptors-
signaling pathways in response to bacterial products or pathogenic bacteria (79-81). 
Establishing the potential interaction of B. burgdorferi lipoproteins with CASR-mediated 
activation will require further studies. 
 Although we did not measure the expression of CD36 on the PM surface after 
Borrelia challenge, our data suggest that anti-CD36 antibody interacts with this member 
of the scavenger receptor B family on murine PMs by reducing the uptake of wild-type 
and ospC mutant spirochetes. Furthermore, elicited murine PMs are known to express 
CD36 even under basal culture conditions and recognize diacylated microbial 
lipopeptides that signal via the TLR2/6 heterodimers (275). Thus, as shown with the 
scavenger receptor A family in a previous B. burgdorferi study (243), it is tempting to 
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speculate that CD36 expression is also upregulated during phagocytosis of spirochetes, 
perhaps via recognition of Borrelia diacylated antigens (275, 276). It will be important to 
determine the role of CD36-mediated recognition and uptake of B. burgdorferi by murine 
macrophages in the future, to better understand CD36-mediated responses in host defense 
and inflammation during Lyme borreliosis.  
Cytokine expression of cells in response to the ospC mutant 
  Previous studies have investigated whether the ospC mutant elicits in human 
epidermal keratinocytes and dermal fibroblasts and murine BMDM a different pattern of 
cytokine and/or chemokine production when compared to these cells infected with the 
wild-type strain (99, 277, 278). In one report, secretion of IL-8, a chemotactic and 
inflammatory cytokine, was analyzed in human keratinocytes that were infected in vitro 
with either the wild-type, the ospC mutant, or the ospC complemented strain at an MOI 
of 100:1 for 24 h. This study proposed that secretion of IL-8 by keratinocytes is 
dependent on OspC as keratinocytes infected with the ospC mutant secreted less IL-8 
when compared to keratinocytes infected with either the wild-type or the ospC 
complemented strain (277). Other reports showed that OspC did not have an effect on the 
production of IL-8 or KC (a murine IL-8 homolog) in human fibroblasts and murine 
BMDM after infection with wild-type, ospC mutant, or ospC complemented spirochetes 
(99, 278). In addition, OspC did not appear to have an effect on the expression and 
production of TNF-α and IL-10 in murine BMDM infected at an MOI of 10:1 for 3 h 
with either the wild-type, ospC mutant or ospC complemented strain. This finding is 
consistent with our results showing no differences in TNF-α and IL-10 expression in 
murine PMs infected with either the wild-type or the ospC mutant strain at an MOI of 
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100:1 for 2 h. Interestingly, the highest level of TNF-α expression in PMs infected with 
the ospC mutant occurred at 2 h post-challenge, which is when phagocytosis of the ospC 
mutant is significantly higher than the wild-type or the ospC complemented strains in our 
studies. This observation may be related to the quantity of spirochetes that are 
internalized by macrophages at a given point in time. In future studies, it would be 
valuable to determine if this relationship occurs by measuring TNF-α secretion in context 
of phagocytosis of spirochetes. 
Phenotype of the ospC mutant in mice when inoculated with a high dose 
 We observed that the ospC mutant was capable of establishing infection and 
disseminating to multiple tissues in mice when inoculated with a high dose (106). This 
finding is in agreement with a recent report showing that the same ospC mutant (ospCK1) 
could establish infection in both wild-type C3H and SCID mice when inoculated at a high 
dose (107). However, Tilly et al. (107) did not report the contribution of the ospC mutant 
to disease development and persistence in mice when inoculated at a high dose. We 
observed that ear punch biopsies from SCID and C3H/HeN mice inoculated with the 
ospC mutant were culture positive 10 days later than ear punch biopsies collected from 
mice that were infected with the wild-type strain.  In addition, we observed that the ospC 
mutant induced marked inflammation in the tibio-tarsal joints of infected SCID mice at 4 
weeks post-challenge. Joint swelling or histological evidence of arthritis in tibio-tarsal 
joints was also present in NODSCIDg and C3H/HeN with active ospC mutant infection. 
Thus, although OspC is one of the major virulence factors of B. burgdorferi to infect 
mice (49, 64, 65), our data showed the requirement of OspC for establishing mammalian 
infection is not absolute and could be overcome by a large inoculum. The fact the ospC 
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mutant disseminates to multiple tissues distant from the site of inoculation also suggest 
that ospC-deficient spirochetes are motile during murine infection when using this large 
inoculum. Although the mechanism for this dose-dependent phenotype is not clear, our 
findings were consistent with the phenotype displayed by other B. burgdorferi mutants 
such as the dbpAB mutant. For example, the dbpAB mutant is not infectious when 
inoculated with doses ranging from 102-104 spirochetes per mouse (87)  but is fully 
infectious when inoculated with a dose of 106 spirochetes per mouse (86, 87). In mice, 
low and intermediate doses (102-105) of the dbpAB mutant have been used to study 
dissemination, tissue colonization, persistence, tick acquisition and transmission (87, 279, 
280); whereas, the high dose (106) of the dbpAB mutant have been used to study disease 
development and persistence in mice (86). Thus, the use of the high dose of the ospC 
mutant represents an alternative method to study the contribution of OspC in disease 
development, tissue tropism and/or persistence.  
Part-II Role of B. burgdorferi EF-Tu during Lyme borreliosis 
 In recent years a growing number of highly conserved bacterial proteins that are 
commonly involved in metabolic regulation or cell stress responses have shown 
additional biological functions involved in bacterial adaptation, virulence, and/or immune 
modulation (196, 197). One such moonlighting protein is enolase that localizes on the 
surface of B. burgdorferi and has properties associated with spirochetal adhesion and 
immunogenicity. Previous studies with B. burgdorferi lysates have found that additional 
cytosolic proteins such as GroEL (bb0649), GAP (glyceraldehyde-3-phosphate-
dehydrogenase, bb0057), and EF-Tu can be associated with the spirochetal membrane in 
variable amounts (192, 193, 281). In this dissertation, we found that rEF-TU was often 
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recognized by antibodies from sera from infected mice and patients diagnosed with Lyme 
disease, suggesting a potential role of EF-Tu as a serodiagnostic marker for Lyme 
disease. In addition, our results showed that EF-Tu does not appear to be exposed on the 
cell surface but indicates a subsurface localization in B. burgdorferi as EF-Tu was 
detected in protoplasmic cylinder fractions and in small quantities in OMVs.  
EF-Tu is immunogenic during Lyme borreliosis 
 According to the CDC, serodiagnosis of Lyme disease should rely on the 
detection of class specific IgM and IgG antibodies individually or combined against 
diagnostically important purified antigens using a two-tiered approach consisting of 
ELISA followed by immunoblotting confirmation of results that are positive or equivocal 
(25). Immunoreactivity of these purified antigens appeared to be dependent on the 
duration of infection and the stage of Lyme disease. Of these proteins, surface 
lipoproteins OspC (22 kDa) and BmpA (39 kDa) and periplasmic FlaA (41 kDa) have 
been suggested as antigens that induce IgM responses during early Lyme borreliosis. Up 
to ten antigens have been suggested to elicit specific IgG responses for disseminated 
infection and late clinical manifestations of Lyme borreliosis (25, 26). Our 
immunoblotting results showed that rEF-Tu was recognized by antibodies from pooled 
mouse sera collected at the early and disseminated stages of infection. In addition, 7 out 
10 patients with a history of prior tick exposure or infection and with early or late clinical 
manifestations were seroreactive to rEF-Tu. Thus, our findings suggest that rEF-Tu is 
recognized by IgM and IgG antibodies as this protein reacted with mouse and human sera 
collected at different stages of Lyme borreliosis. 
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 Other B. burgdorferi periplasmic and cytoplasmic proteins have been shown to be 
immunogenic in human sera from Lyme disease patients (26, 193, 282, 283). Of these 
proteins, FlaB (33 kDa) and FlaA are highly reactive to IgM antibodies during the first 4 
weeks of illness, and the protoplasmic protein p83/100 (83-100 kDa) is highly reactive to 
IgG antibodies in patients with late Lyme borreliosis (26, 284). Our data suggested that 
EF-Tu triggers an IgM-mediated response during early Lyme borreliosis as rEF-Tu 
exhibited reactivity with antibodies from infected mice within the first 4 weeks post-
challenge. This finding suggests the role of B. burgdorferi EF-Tu as a potential early 
marker of Lyme borreliosis. In fact, this observation is consistent with a previous study 
showing that Borrellia hermsii EF-Tu was strongly reactive with IgM antibodies during 
early spirochetal infection in mice. However, because EF-Tu is a highly conserved 
protein among spirochetal species (285), this raises the possibility that this antigen may 
cross-react with IgM antibodies elicited from prior exposure to other spirochetal 
infections, as shown with FlaB that cross-reacts with antibodies from other spirochetal 
species (286, 287). In contrast, EF-Tu from other bacterial pathogens can elicit specific 
IgG-mediated responses during these bacterial infections (205, 249, 250). It is possible 
that the appearance of anti-EF-Tu IgG in mouse and human sera occurs after B. 
burgdorferi is killed by phagocytes, as our findings showed that B. burgdorferi EF-Tu 
was primarly localized in the cytoplasmic compartment. Further studies are needed to 
characterize the subclasses of immunoglobulins produced against B. burgdorferi EF-Tu 
at different stages of Lyme disease. 
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EF-Tu is not protective against B. burgdorferi challenge in vivo 
 Although B. burgdorferi EF-Tu appeared to elicit an antibody response in vivo, 
our active immunization experiments suggest that these anti-EF-Tu antibodies were not 
bactericidal during Lyme borreliosis as they were unable to reduce spirochetal burden in 
joints or in engorged tick larvae from immunized mice. One possible explanation of this 
lack of protection against spirochetal challenge could be because recombinant EF-Tu is 
not expressed in its native form in E. coli, which can lead to conformational changes in 
putative protective epitopes that may exist on EF-Tu. Given that our proteinase K and 
microscopy findings showed that EF-Tu was not on the cell surface, another possibility 
for this lack of protective phenotype could be attributed to changes in cytoplasmic EF-Tu 
after its degradation within antigen presenting cells. This biological process may lead to 
the generation of non-protective immunogenic soluble peptides that are presented via 
MHC-class II to naive CD4+ T cells for a T cell-dependent B cell antibody response 
(103).  
Localization of EF-Tu in B. burgdorferi 
 Our findings showed that B. burgdorferi EF-Tu predominantly localizes in PC 
fractions and is present in OMVs fractions in small quantities. Gram-negative bacteria 
naturally secretes outer membrane vesicles to deliver biologically active molecules and to 
interact with other cells in their environment (288). These vesicles are primarily 
composed of outer membrane proteins and periplasmic-associated proteins and enzymes 
(193, 289, 290). B. burgdorferi has shown to be able to produce OMVs when grown in 
BSK culture media without serum (291), a phenomenon that is also detected when 
spirochetes are co-culture with mammalian cells (292, 293) and during infection in Lyme 
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disease patients (293-295). It is thought that B. burgdorferi releases OMVs in response to 
physiological stress in vivo (296). These OMVs can serve as an adhesin on endothelial 
cells (297) and a mitogen for B cell responses in vivo (254). Thus, one might speculate 
from these observations that B. burgdorferi EF-Tu may have a function in OMVs, given 
that this protein appears to be immunogenic in vivo, and another highly conserved soluble 
enzyme such as enolase has been shown to be released in OMVs serving as an 
immunogenic plasminogen-binding protein (193). However, the biological function of 
OMVs biogenesis and constituents during B. burgdorferi infection is not completely 
understood. 
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CHAPTER VI: FUTURE DIRECTIONS 
 The data presented in this dissertation contribute to the current understanding of 
the biological function of OspC during mammalian infection and explore the role of EF-
Tu during Lyme borreliosis. We demonstrated that depletion of phagocytes at the skin-
site of inoculation in SCID mice allowed the ospC mutant to establish infection in vivo. 
In phagocyte-depleted SCID mice, the ospC mutant was capable of colonizing the tibio-
tarsal joints and triggered neutrophilia during dissemination in a similar pattern as wild-type 
bacteria. Furthermore, in vitro studies showed that phagocytosis of the ospC mutant was 
significantly higher than the wild-type and ospC complemented strains, suggesting that 
OspC could have a protective role against macrophage phagocytosis. OspC was not 
involved in scavenger receptor A and B mediated phagocytosis of spirochetes by murine 
macrophages. Thus, these data reveal that OspC has an anti-phagocytic property, which 
may facilitate the evasion of spirochetes from phagocytes during early infection. 
 In addition, data from second part of this dissertation showed that B. burgdorferi 
EF-Tu triggered an antibody response during Lyme borreliosis. Our findings suggest that 
B. burgdorferi EF-Tu is an immunogenic antigen and may have epitopes that could be 
used to assist in the serodiagnosis of early Lyme borreliosis. These putative EF-Tu 
epitopes are likely not accessible to antibodies in intact B. burgdorferi during infection as 
we demonstrated that EF-Tu primarily localizes underneath the cell surface of spirochetes 
that were grown under favorable culture conditions. 
Assess the interaction of B. burgdorferi OspC with macrophages in mice 
Our findings suggest that OspC protects wild-type spirochetes when they 
encounter macrophages in the skin during early infection in SCID mice. To confirm the 
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contribution of these phagocytes to the clearance of the ospC mutant in mice, we will 
deplete these cells with clodronate liposome treatments in the skin of C3H/HeN mice as 
previously described in materials and methods for SCID mice. We will use the C3H/HeN 
mouse strain since this is the experimental mouse model for Lyme borreliosis (34). 
Infectivity of C3H mice will be analyzed by reisolation of the ospC mutant from different 
tissues 7 days post-challenge as described in infectivity studies conducted with SCID 
mice. If the ospC mutant disseminates in C3H mice treated with clodronate liposomes, 
this finding will support the notion that OspC plays a protective role for spirochetes 
against macrophages. Conversely, if the ospC mutant cannot establish infection in C3H 
mice treated with clodronate liposomes, this finding suggests that depletion of phagocytes 
along with B and T cells is needed for the ospC mutant to infect mice. This scenario 
implies that the ospC mutant has a reduced fitness and is less able to adapt in the mouse 
skin when compared to the wild-type strain. 
Our IHC results showed that F4/80+ cells were depleted in the skin of SCID mice 
infected with wild-type or ospC mutant spirochetes. In the mouse skin, resident dermal 
macrophages and immature epidermal Langerhans cells can express the F4/80 
glycoprotein on the cell surface (236, 264). To rule out the possibility that Langerhans 
cells are involved in the clearance of the ospC mutant, we can test this question by 
depleting these cells from the mouse epidermis prior to inoculation with either the wild-
type or the ospC mutant strain. A suitable mouse model to test this question is the 
Langerin-DTR transgenic mouse strain, as treatment with diphteria toxin in this mouse 
strain selectively depletes epidermal Langerhans cells, dermal DC, and some lymphoid 
derived DC for at least 5 days (298), without causing an increase in neutrophils as shown 
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with other mouse strains used for DC depletion such as CD11b- or CD11c-DTR mice 
(298, 299). A similar mouse strain has been used by Lyme disease investigators to test 
whether a B. burgdorferi p66 mutant could establish infection in mice depleted of DCs 
and certain monocyte populations. This B. burgdorferi mutant had a similar pattern of 
clearance in vivo as shown by the ospC mutant and could not establish infection in 
dendritic cell-depleted, TLR2-/-, and MyD88-/- mice (85). Thus, based on this evidence, it 
is possible that depletion of DCs may not be sufficient for the ospC mutant to establish 
infection in mice.   
In addition, it will be important for this project to use additional approaches to 
better understand how wild-type and ospC mutant spirochetes move in the skin of mice 
and interact with phagocytes in vivo. To assess how these spirochetes move in the skin, 
GFP-expressing spirochetes generated in this study could be used to assess whether the 
ospC mutant exhibits different movements than the wild-type in the mouse skin, using 
intravital microscopy. In the past 5 years, this technique has been employed to 
characterize the movement of GFP-expressing B. burgdorferi wild-type and mutant 
strains in the mouse skin and organs (79, 300), as most in vitro systems used to examine 
the motility of B. burgdorferi do not resemble the tissue milieus that spirochetes 
encounter in vivo (300). This technique has shown that B. burgdorferi exhibits at least 
three different motility states in the mouse dermis and has been used to assess the 
interaction of B. burgdorferi adhesins such as BBK32 with vascular endothelium (301, 
302). By understanding the kinetics and movements of wild-type and ospC spirochetes in 
the mouse dermis, we will be able to assess whether the ospC mutant has a defective 
phenotype in migrating from connective tissue into the vasculature. If this defect occurs, 
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then ospC mutant spirochetes may be captured more efficiently by resident macrophages 
or Langerhans cells than wild-type spirochetes in the mouse skin. This phenotype could 
explain why the ospC mutant is rapidly cleared within 48 h from the skin-site of 
inoculation in mice, without a marked neutrophil recruitment into the mouse skin (64, 
99). Alternatively, if the ospC mutant exhibits a similar pattern of motility to the wild-
type in vivo, this finding would support the importance of OspC as a surface receptor for 
host cells or ligands in the mouse skin. 
To evaluate the interaction of the wild-type and ospC mutant with phagocytes in 
vivo, we could test this by inoculating monomeric red fluorescent protein (mRFP)-
expressing spirochetes in Macgreen transgenic mice and then image sections of the 
mouse skin using intravital microscopy. We will need to transform wild-type and the 
ospC mutant spirochetes with our construct that already contains the mRFP). The 
Macgreen mouse line express the enhanced green fluorescent protein (EGFP) reporter 
gene that is driven by the macrophage colony-stimulating factor receptor 1 (csf1r) 
promoter (303). Previous studies have shown that treatment of mice with the monoclonal 
anti-csfr1 antibody blocks csf1 signaling and efficiently depletes the number of F4/80+ 
phagocyte populations in the skin (299). Thus, this approach will determine whether there 
are differences in the behavior between the ospC mutant and the wild-type strain when 
individual phagocyte populations are depleted in the mouse dermis and epidermis.  
Identify the phagocytic receptor and mechanism involved in the uptake of the ospC 
mutant 
 Our results showed an enhanced uptake of the ospC mutant strain when compared 
to the wild-type using fluorometric based phagocytosis assays and flow cytometry. In 
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addition, we evaluated whether the scavenger receptor A and B were involved in this 
enhanced uptake of the ospC mutant and found scavenger receptor A and B mediated 
phagocytosis of spirochetes was independent of OspC. To evaluate the phagocytic 
receptor(s) that are involved during phagocytosis of the ospC mutant by murine 
macrophages, we could measure the cell surface expression of different phagocytic 
receptors in murine PMs before and after phagocytosis of the ospC mutant and the wild-
type strain. Some phagocytic receptors involved in the binding and/or uptake of non-
opsonized spirochetes include: MARCO, SRAI/II, CR3, CD14, and mannose (125, 138, 
244). Other macrophage receptors that could be evaluated are those that have an 
inhibitory effect in phagocytosis (e.g. FcγIIB), as these receptors have motifs that recruit 
phosphatases that play an inhibitory function in phagocytosis (304). It will also be 
important to evaluate the expression of scavenger receptor CD36 in macrophages during 
B. burgdorferi challenge, as CD36 has been reported to mediate phagocytosis of different 
bacterial species (246). In addition, it is possible that CD36 could play a role in the 
pathogenesis of Lyme carditis or neuroborreliosis, as this pattern recognition receptor is 
expressed in several cell types (e.g. monocytes/macrophages, endothelial cells, cardiac 
myosites, platelets, and adiposytes) (305) and mediates several biological process, 
including inflammation of cardiovascular and neurodegenerative disorders, angiogenesis, 
thrombosis, oxidative stress, and metabolism (306). Thus, measuring the surface 
expression of different phagocytic receptors will allow us to obtain baseline data when 
murine PMs interact with either wild-type or ospC mutant spirochetes. This will allow us 
to determine whether OspC alters phagocytic receptor profiles in infected murine 
macrophages. One possible outcome of this experiment is that more than one phagocytic 
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receptor is involved in the higher uptake of the ospC mutant by PMs. Therefore, blocking 
multiple phagocytic receptors may be needed to show similar phagocytosis between the 
ospC mutant and the wild-type strain. Another possible scenario is that one phagocytic 
receptor mediates the recognition of OspC in spirochetes. If this occurs, research efforts 
will be directed to understand the interaction of OspC with their potential cognate 
receptor on macrophages. To further our understanding of this interaction, it will be 
important to ectopically express this phagocytic receptor on CHO cells to characterize the 
contribution of this receptor in binding OspC and phagocytizing spirochetes. For this 
experiment we would use CHO cells, as they stably express CR3 and have the ability to 
bind non-opsonized spirochetes and outer membrane lipoproteins such as OspA/B as well 
as phagocytose B. burgdorferi (138, 307). If OspC specifically interacts with one 
phagocytic receptor, we could then evaluate whether blocking this receptor would enhace 
the ability of macrophages to clear B. burgdorferi during early stages of infection in vivo.  
 Another possible outcome is that blocking phagocytic receptors do not restore 
phagocytosis of the ospC mutant to levels that are similar to those shown by wild-type 
spirohetes in PMs. This finding suggests that an additional mechanism such as coiling 
phagocytosis could mediate this enhanced uptake of the ospC mutant. To test this, murine 
PMs will be infected at an MOI of 100:1 with either wild-type or the ospC mutant strains 
expressing GFP, and coilining phagocytosis events will be enumerated by confocal laser 
scanning microscopy. To visualize the formation of actin-rich pseudopods that enwrap 
spirochetes in coiling phagocytosis, we could then use a probe such as phalloidin that 
binds with a high affinity to F-actin filaments in macrophages. In addition, we could 
employ an alternative method to block uptake of GFP-expressing spirochetes via coiling 
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phagocytosis. Murine macrophages will be transfected with small interfering RNA 
(siRNA) to knockdown formin FMNL1 and mDia1 which have shown to regulate coiling 
phagocytosis of B. burgdorferi (139). Phagocytosis of GFP-expressing spirochetes by 
siRNA-treated macrophages will be determined using a microplate fluorometer.  
 Our findings suggest that OspC could directly protect spirochetes against 
macrophage phagocytosis. Thus, another possibility is that OspC shields ligands on the 
spirochete’s membrane from interacting with macrophages via conventional 
phagocytosis. For example, it is possible that macrophage receptors recognize ligands 
known as “eat me signals” (308) on the outer membrane of spirochetes lacking OspC, 
which lead to an enhanced uptake of the ospC mutant when compared to the wild-type 
strain.  As mentioned above, it is known that macrophage phagocytosis of B. burgdorferi 
could be mediated by several phagocytic receptors and pattern-recognition receptors 
(125). It would be then important to evaluate whether OspC could have an effect on 
signaling via tyrosine kinases (e.g. PI3K) or serine/threonine kinases (e.g. RhoA kinase) 
that are known to regulate cytoskeletal activities during phagocytosis of bacteria (141, 
309). To test this, we could measure the phosporylation of PI3K and RhoA kinases in 
cellular lysates from PMs infected (MOI of 100:1) with either wild-type or ospC mutant 
spirochetes. If OspC has an effect in the activation of these kinases, we can next confirm 
whether blocking PI3K or RhoA pathway inhibits the uptake of the ospC mutant to levels 
that are similar to those shown by the wild-type strain. Murine PMs will be then 
pretreated with pharmacological inhibitors specific for PI3K and/or RhoA kinases, and 
phagocytosis of GFP-expressing spirochetes could be determined using a microplate 
fluorometer. 
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 Because B. burgdorferi encodes several outer surface proteins that can be 
expressed at specific stages of mammalian infection (76), it will also be important to 
evaluate whether other surface proteins exhibit a similar protective phenotype against 
macrophage phagocytosis in vitro. It is possible that this anti-phagocytic property of 
OspC is not unique, and perhaps, other surface lipoproteins important for mammalian 
infection may also protect against macrophage phagocytosis. To test this, non-opsonic 
phagocytosis could be assessed for several GFP-expressing B. burgdorferi single and 
double mutant strains that were generated in the lab. If other mutants showed an 
enhanced uptake by macrophages, this finding will suggest that B. burgdorferi employs 
certain surface proteins to protect from macrophage phagocytosis. Another possible 
outcome is that this protection against macrophage phagocytosis is restricted to OspC. 
This finding could be explained because OspC is an immunodominant antigen on the 
spirochetal membrane during the early course of infection (172, 173). It is well-known 
that B. burgdorferi upregulates the production of OspC as spirochetes are transmitted 
from ticks to mammals as a strategy to survive and adapt in the mammalian host 
environment (14, 171). However, OspC is downregulated in response to anti-OspC IgG 
antibodies within the first 2-3 weeks post-infection (174, 175). Therefore, this protective 
effect of OspC against macrophage phagocytosis could be specific to the early stage of 
mammalian infection. A proposed model of the functions of OspC during early Lyme 
borreliosis are represented in figure 33. 
Characterize B. burgdorferi EF-Tu as a serodiagnostic marker of Lyme disease 
 Our data showed that rEF-Tu is recognized by antibodies in samples from 
infected mice and Lyme disease patients. To validate these findings and determine the 
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type of humoral responses, it will be then important to develop an ELISA to determine 
the frequency and duration of IgM and IgG specific antibodies from infectious sera from 
mice and humans collected at different stages of Lyme borreliosis. Then, immunoblotting 
can be used as a confirmatory tool for ELISA positive or equivocal results. These 
serological findings would be more meaningful if the sample size is increased for each 
group of Lyme disease patients to determine the sensitivity and specificity of each 
serological assay. To design this study, each stage of the illness and laboratory test results 
should be used to define an inclusion and exclusion criteria of the patient samples that 
will be analyzed by serology. It will also be important to evaluate how these results 
compare to current antigens that are used for the serodiagnosis of Lyme disease such as 
OspC and p83/100 for the early and late stages of illness, respectively (25, 26). 
Furthermore, as B. burgdorferi EF-Tu is a highly conserved antigen among Borrelia 
species (285), it will also be necessary to include other rEF-Tu antigens from other 
Borrelia species and bacterial species to assess cross-reactivity of IgM and IgG 
antibodies in samples tested by this newly developed ELISA. After performing these 
predicted experiments and if results demonstrate that EF-Tu could be used as a 
serodiagnostic marker for Lyme disease, it would then be appropriate to define the 
immunodominant epitopes that could be present in B. burgdorferi EF-Tu protein, which 
could be tested by this ELISA. We have preliminary performed sequence alignment of 
the full-length EF-Tu sequence among different pathogenic spirochetal species (e.g. B. 
burgdorferi, Leptospira interrogans, Treponema pallidum, Treponema denticola) and 
found that sequence homologies varied from 64% to 68% among these spirochetal 
species (data not shown). Therefore, we could start screening unique B. burgdorferi EF-
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Tu peptides against serum panels from patients with early and late manifestations of 
Lyme disease. 
 
 
Figure 27. Proposed model of the functions of OspC during early Lyme borreliosis. 
Simplified illustration of the main cellular effectors involved in host defense during 
spirochetal infection within the murine epidermis and dermis (panel was adapted from 
(310)). Previous studies have shown that OspC binds to tick salivary proteins such as 
Salp15 which can protect spirochetes from complement- and antibody- mediated killing 
(111, 178). Alternatively, other studies have shown that OspC is a potent plasminogen 
receptors which may facilitate dissemination of spirochetes in vivo. Our studies show that 
 121 
 
OspC could have anti-phagocytic property (bold font) that reduces phagocytosis of 
B.burgdorferi strains by murine and human macrophages. The mechanism for how 
phagocytosis is different between the wild-type and ospC mutant strains is under 
investigation. Conventional and coiling phagocytosis are the two major mechanisms that 
may be involved in the recognition and binding of spirochetal ligands. Our data 
demonstrate that B cells, T cells, NK cells, and neutrophils are not required for the 
clearance of the ospC mutant; however, F4/80+ phagocytes such as macrophages and 
Langerhans cells play a role in the clearance of the ospC mutant in vivo. The role of 
keratinocytes, dermal dendritic cells (DC), eosinophils, and mast cells were not evaluated 
in our studies.     
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APPENDIX 
Evaluation of Stat3 deficiency in endothelial cells and myeloid cells during Lyme 
borreliosis 
 The signal transducer and activator of transcription 3 (STAT3) has been shown to 
be important in several biological processes, including cell proliferation, migration, 
survival, and transformation, and angiogenesis (311). STAT3 is also an important 
regulator of inflammatory and immune responses in diverse pathological processes, 
including myocarditis, rheumatoid arthritis, and central nervous system autoimmune 
diseases (312-314), but its role in Lyme borreliosis is not well understood. Previously, a 
report from Behera et al. (315) showed that B. burgdorferi infection induced the 
phosphorylation and nuclear translocation of STAT3 in primary human chondrocytes. 
Another report indicated that STAT3 expression and phosphorylation was upregulated in 
cardiac tissues from C3H and Balb/c mice infected with B. burgdorferi, and this 
upregulation of STAT3 was associated with the progression of disease (316). B. 
burgdorferi lipoproteins also induce NF-κB nuclear translocation in myeloid and 
endothelial cells, resulting in cytokine and chemokine production and adhesion molecule 
expression (119). Because STAT3 inhibits the expression of NF-κB-regulated gene 
products involved in innate immunity and T helper 1 adaptive responses important for 
controlling microbial infections and inflammation (311), we then hypothesized that Stat3 
deficiency in endothelial or myeloid cells exacerbates inflammation in joints during 
Lyme borreliosis. To test this hypothesis, we used endothelial cell- (Figure 28A) or 
myeloid cell-specific (Figure 30A) Stat3-deficient mice (Stat3E-/- or Stat3B-/-) that were 
challenged with B. burgdorferi 5A4NP1 strain. Our preliminary results showed that all 
 123 
 
three B. burgdorferi infected Stat3E-/- mice exhibited mild to moderate arthritis in tibio-
tarsal joints at 4 weeks post-challenge. B. burgdorferi infected Stat3F/F (control, n = 5) 
mice exhibited minimal to mild arthritis in tibio-tarsal joints (Figure 29). No significant 
differences in spirochetal burden in tissues and granulocyte and mononuclear cell counts 
in blood were noted between Stat3E-/- and Stat3F/F mice at 4 weeks post-challenge (Figure 
28B-D). B. burgdorferi infected Stat3B-/- mice (Figure 31A, n = 2) also exhibited mild 
arthritis in tibio-tarsal joints at day 10 post-challenge. B. burgdorferi infected Stat3F/F 
(control, n = 5) mice exhibited minimal to mild arthritis in tibio-tarsal joints (Figure 
31A). Spirochetal burden in the heart and tibio-tarsal joint was similar between Stat3B-/- 
and Stat3F/F mice at day 10 post-challenge (Figure 30B). These preliminary findings 
suggest that Stat3 in endothelial cells may contribute to the resolution of arthritis in mice, 
as all three Stat3 E-/- mice appeared to have higher arthritis than the control group.  Future 
studies should expand these preliminary findings to determine the role of Stat3 in 
endothelial cells in the development of arthritis in mice.   
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Figure 28. Spirochetal burden in tissues and leukocyte response in circulation of 
Stat3E-/- mice during disseminated B. burgdorferi infection. A) Demonstration of 
genotypes of eTie2-Cre (upper, Cre product = 300 bp) and Stat3 floxed alleles (lower, 
Stat3 floxed product = 520 bp) of mice used in this study. The eTie2 gene promoter 
drives the expression of Cre recombinase for the deletion of loxP flanked Stat3 in 
endothelial cells. The genotype for mice 17, 19, and 20 was Stat3F/F/eTie2-Cre, 
suggesting that stat3 was deleted in endothelial cells in these mice (named as Stat3E-/-). 
Mice 16 and 18 were littermate controls (named as Stat3F/F). B) Spirochetal burden in 
inguinal lymph nodes, skin biopsies, and apex of hearts from mice (n = 2-3 per group) at 
4 weeks (wk) post-challenge with B. burgdorferi 5A4NP1 strain (106 spirochetes 
inoculated per mouse via i.d.). B. burgdorferi was reisolated from all tissues tested by 
PCR. C-D) Granulocytes (left) and mononuclear cell (right) responses in peripheral blood 
of mice (n = 3-5 per group) infected with B. burgdorferi 4 weeks post-challenge. 
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Peripheral blood was analyzed with a HEMAVET 950 multispecies hematology cell 
counter as described in material and methods. Normal reference values for neutrophils, 
eosinophils, monocytes and lymphocytes in mice are ≤ 2.5, ≤ 0.2, ≤ 0.4, and 0.9 - 9.3 (x 
103/µl), respectively (NS = not significant).  
 
 
Figure 29. Arthritis severity in tibio-tarsal joints in B. burgdorferi-infected C57BL/6 
(B6) Stat3F/F and Stat3E-/- mice at 4 weeks post-infection. Representative images 
(magnification, ×2.5, scale bar- 400 μm) of H&E-stained tibio-tarsal joints from BSK-
injected (control) and 4 week-infected Stat3F/F and Stat3E-/- mice. Blinded 
histopathological evaluation of tibio-tarsal joints of mice was performed by a board 
certified veterinary pathologist. Stat3F/F mice 16 and 18 exhibited minimal to mild 
inflammation of the ligament or tendon sheaths (herein collectively termed arthritis, black 
arrows) with cellular infiltrates primarily composed by macrophages, lymphocytes, and 
plasma cells and occasionally by neutrophils. Mouse 18 exhibited evidence of periosteal 
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inflammation and bone erosion and remodeling on random focal areas of the periosteum 
in the tibia (left black arrow). Stat3E-/- mice 17, 19, and 20 exhibited mild to moderate 
inflammation of the ligament or tendon sheaths (black arrows) as well as the periosteum, 
which had focal areas of bone erosion and remodeling. Cellular infiltrates of mice 17 and 
19 were primarily composed of macrophages, lymphocytes, and plasma cells. Mouse 20 
also exhibited moderate inflammation characterized by a mixture neutrophil and 
mononuclear cell (macrophages, lymphocytes, and plasma cells) infiltration in multiple 
areas throughout the fascia (black arrow) and muscle (collectively termed fasciitis and 
myositis, respectively).  
 
 
Figure 30. Spirochetal burden in tissues of mice deficient for Stat3 in myeloid cells 
infected with B. burgdorferi for 10 days. A) Demonstration of genotypes of bTie2-Cre 
(upper, Cre product = 300 bp) and Stat3 wild-type (WT) and Stat3 floxed alleles (lower, 
Stat3 WT = 361 bp and Stat3 floxed = 377 bp) of mice. The bTie2 gene promoter drives 
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the expression of Cre recombinase for the deletion of loxP flanked stat3 in myeloid cells. 
The genotype for mice 205 and 213 was Stat3F/F/bTie2-Cre, suggesting that stat3 was 
deleted in myeloid cells in these mice (named as Stat3B-/-). Representative genotyping 
results of Stat3F/F mice (200, and 219), Stat3 WT mice (102), and Cre+ F/F mice (20) are 
shown in this figure as controls from PCR reaction. B) Spirochetal burden in apex of 
hearts and tibio-tarsal joints from mice (n = 2-5 per group, NS = not significant) at 10 
days post-challenge with B. burgdorferi 5A4NP1 strain (105 spirochetes inoculated per 
mouse via i.d.).  
 
 
Figure 31. Arthritis severity in tibio-tarsal joints in B. burgdorferi-infected C57BL/6 
(B6) Stat3F/F and Stat3B-/- mice at 10 days post-infection. Representative images 
(magnification, ×2.5, scale bar- 200 μm) of H&E-stained tibio-tarsal joints from BSK-
injected (control) and 4 week-infected Stat3F/F and Stat3B-/- mice. Blinded 
histopathological evaluation of tibio-tarsal joints of mice was performed by a board 
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certified veterinary pathologist. Stat3F/F mice 211, 214, and 216 exhibited minimal to 
mild inflammation of the synovial membrane and ligament or tendon sheaths (herein 
collectively termed arthritis, black arrows) with cellular infiltrates primarily composed of 
neutrophils and macrophages with few lymphocytes and plasma cells. Stat3F/F mice also 
exhibited evidence of mild fasciitis and myositis and periosteal inflammation. Stat3B-/- 
mice 205, and 213 exhibited mild inflammation of the synovial membrane (black 
arrows), the ligament or tendon sheaths and the fasciae and muscle. Cellular infiltrates of 
these mice were primarily composed by neutrophils and macrophages with some 
lymphocytes, and rare plasma cells.  
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Evaluation of Plac8 and nitric oxide deficiency in host defense and disease during 
Lyme borreliosis 
 Infection with the Lyme disease spirochete, B. burgdorferi, causes a debilitating 
inflammatory disorder in humans that primarily targets the skin, joints, heart, and nervous 
system. The outer surface lipoproteins of B. burgdorferi have shown to stimulate the 
production of inflammatory mediators such as cytokines and nitric oxide (NO) that can 
regulate the innate immune responses during Lyme borreliosis (170). B. burgdorferi also 
has shown to be highly susceptible to killing by NO donor compounds (152) and by 
iNOS-derived NO from macrophages (148, 155, 170). However, despite the sensitivity of 
B. burgdorferi to NO compounds in vitro, no critical differences in spirochetal burden 
and joint inflammation are observed between wild-type and iNOS-deficient mice (157, 
317). These findings suggest that an additional compensatory antimicrobial mechanism is 
required to clear B. burgdorferi infection in tissues in mice. To determine if an additional 
mechanism is involved in killing B. burgdorferi in vivo, we then preliminary evaluated 
the role of Plac8 in host defense and disease during Lyme borreliosis. Plac8 is a cysteine-
rich protein that is expressed by macrophages, neutrophils, lymphocytes, and epithelial 
cells and is involved in host defense against extracellular and intracellular bacterial 
infections in mice (318, 319). Two iNOS-deficient Plac8-/- mice and two Plac8-/- mice 
were challenged with B. burgdorferi B31-A3 strain. Nitric oxide production was 
inhibited by administration of 50 μM of the NO inhibitor (NOI), L-NMMA, to the 
drinking water on two days before infection through day 25 post-infection. Our 
preliminary results showed that iNOS-deficient Plac8-/- mice exhibited slightly higher 
spirochetal burden in inguinal lymph node, heart, and tibio-tarsal joint when compared to 
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Plac8-/- mice (Figure 32A). Both groups of infected-mice exhibited a similar pattern of 
inflammation in the tibio-tarsal joints at 3.5 weeks post-challenge (Figure 33A). These 
findings suggest that Plac8 deficiency may be involved in the clearance of spirochetes in 
tissues of mice.  Future studies should expand these preliminary findings to determine the 
role of Plac8 in host defense during Lyme borreliosis.  
 
Figure 32. Spirochetal burden in tissues of Plac8-/- mice and Plac8-/- mice treated 
with nitric oxide inhibitor (NOI) at 3.5 weeks post-infection. A) Spirochetal burden in 
ear pinna, inguinal lymph node, apex of hearts, and tibio-tarsal joints from mice (n = 2 
per group) at 3.5 weeks (wk) post-challenge with B. burgdorferi B31-A3 strain (106 
spirochetes inoculated per mouse via i.d.). B. burgdorferi was reisolated from ear punch 
biopsies collected from all mice tested by PCR.  
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Figure 33. Arthritis severity in tibio-tarsal joints in B. burgdorferi-infected C57BL/6 
(B6) Plac8-/- mice and Plac8-/- mice treated with nitric oxide inhibitor (NOI) at 3.5 
weeks post-infection. A) Representative images (magnification, ×2.5, scale bar- 400 μm) 
of H&E-stained tibio-tarsal joints from BSK-injected (control) and 3.5 week-infected 
mice. Blinded histopathological evaluation of tibio-tarsal joints of mice was performed 
by a board certified veterinary pathologist. Plac8-/- mice 104 and 105 exhibited mild 
inflammation of tibio-tarsal joints characterized by mild hyperplasia of the synovial 
membrane and thickening of ligament and tendon sheaths (black arrows). Cellular 
infiltrates were primarily composed of macrophages and lymphocytes and few plasma 
cells. Tibio-tarsal joints from NOI-treated Plac8-/- mice 102 and 103 had mild 
inflammation of the synovial membrane, ligaments and tendon sheaths (black arrows) 
with cellular infiltrates primarily composed of macrophages, lymphocytes, and plasma 
cells.  
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